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Abstract 24 
The cullin-RING ligases (CRLs) form the major family of E3 ubiquitin ligases. The 25 
prototypic CRLs in yeast, called SCF enzymes, employ a single E2 enzyme, Cdc34, to 26 
build poly-ubiquitin chains required for degradation. In contrast, six different human E2 27 
and E3 enzyme activities, including Cdc34 orthologs UBE2R1 and UBE2R2, appear to 28 
mediate SCF-catalyzed substrate polyubiquitylation in vitro. The combinatorial interplay 29 
of these enzymes raises questions about genetic buffering of SCFs in human cells and 30 
challenges the dogma that E3s alone determine substrate specificity. To enable the 31 
quantitative comparisons of SCF-dependent ubiquitylation reactions with physiological 32 
enzyme concentrations, mass spectrometry was employed to estimate E2 and E3 levels 33 
in cells. In combination with UBE2R1/2, the E2 UBE2D3 and the E3 ARIH1 both 34 
promoted SCF-mediated polyubiquitylation in a substrate-specific fashion. Unexpectedly, 35 
UBE2R2 alone had negligible ubiquitylation activity at physiological concentrations and 36 
the ablation of UBE2R1/2 had no effect on the stability of SCF substrates in cells. A 37 
genome-wide CRISPR screen revealed that an additional E2 enzyme, UBE2G1, buffers 38 
against the loss of UBE2R1/2. UBE2G1 had robust in vitro chain extension activity with 39 
SCF, and UBE2G1 knockdown in cells lacking UBE2R1/2 resulted in stabilization of the 40 
SCF substrates p27 and CYCLIN E as well as the CUL2-RING ligase substrate HIF1. 41 
The results demonstrate the human SCF enzyme system is diversified by association 42 
with multiple catalytic enzyme partners.     43 
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Introduction 44 
 In the ubiquitin-proteasome system (UPS), ubiquitin ligases (E3s) bind to protein 45 
substrates to direct poly-ubiquitin chain formation and degradation by the 26S 46 
proteasome. There are at least 600 E3s in the mammalian proteome (Deshaies & 47 
Joazeiro, 2009), and alterations of the expression levels in several E3s or their 48 
substrates have been clinically and biochemically linked to cancer and other diseases in 49 
humans (Skaar et al., 2014; Z. Wang et al., 2014). E3 enzymes recruit both the protein 50 
substrate as well as a ubiquitin-conjugating enzyme (E2) bound to the protein modifier 51 
ubiquitin (Kleiger & Mayor, 2014). E3s promote the covalent modification of a lysine 52 
residue on the E3-bound substrate, in most cases by direct transfer of the ubiquitin 53 
moiety from E2 to substrate (Berndsen & Wolberger, 2014; Metzger et al., 2014; Vittal 54 
et al., 2015). A chain of at least 4 ubiquitins is typically required for recognition by the 55 
26S proteasome (Chau et al., 1989; Thrower et al., 2000). Despite much progress, the 56 
different roles of E2s and E3s in cells remains enigmatic due to a lack of kinetics, a lack 57 
of knowledge of potentially relevant concentrations, and an understanding of how 58 
different E2-E3 combinations may regulate substrate polyubiquitylation. 59 
Some E2s can link ubiquitin directly to substrate in a priming step, whereas other 60 
E2s are dedicated to subsequent cycles of poly-ubiquitin chain extension. Yet other E2s 61 
are competent at both priming and chain extension. However, these properties may 62 
change dramatically as a function of E2 levels, in particular at the high E2 63 
concentrations typically used in in vitro reconstituted ubiquitylation reactions. Although 64 
E2s are clearly harnessed by E3s to transfer ubiquitin (Pickart & Rose, 1985), the 65 
potential combinatorial complexity is overwhelming because many E3s appear to 66 
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collaborate with multiple E2s to promote substrate ubiquitylation (Christensen et al., 67 
2007; Rodrigo-Brenni & Morgan, 2007; Wickliffe et al., 2011). Defining the roles of 68 
particular enzymes and enzyme combinations remains an as yet unmet challenge in 69 
understanding how the UPS controls cellular function.  70 
The Skp1-cullin-F-box (SCF) ubiquitin ligases are a case study for the 71 
combinatorial interplay of E2s during substrate ubiquitylation. SCFs are modular multi-72 
subunit complexes that all contain a common cullin 1 (CUL1) core subunit and a ‘really 73 
interesting new gene’ (RING) domain RBX1 subunit (Harper & Tan, 2012; Lydeard et al., 74 
2013; Zimmerman et al., 2010). CUL1 acts as a scaffold that tethers substrate binding 75 
subunits to the E2-binding subunit: the C-terminal segment of CUL1 binds to the RING 76 
subunit, which in turn recruits the ubiquitin-charged E2, while the N-terminal segment of 77 
CUL1 binds to adaptors called F-box proteins that recruit substrates. SCFs are the 78 
archetypal member of the Cullin-RING ligases (CRLs), which collectively account for at 79 
least 200 of the known E3s in humans (Lydeard et al., 2013). 80 
 The original elucidation of Skp1-cullin-F-box (SCF) ubiquitin ligase function by 81 
genetic and biochemical studies in the budding yeast Saccharomyces cerevisiae, 82 
suggested that Cdc34 is the only E2 enzyme needed for SCF activity (Feldman et al., 83 
1997; Schwob et al., 1994; Skowyra et al., 1997; Verma et al., 1997)}. In human cells, 84 
an understanding of the relationship between Cdc34 and SCF function has been 85 
confounded by the large repertoire of ubiquitin-modifying enzymes associated with SCF 86 
complexes. While the yeast E2s Ubc4/5 do not support SCF activity in vitro, several 87 
human SCF ubiquitylation reactions have been reconstituted with the corresponding 88 
human E2 orthologs UBE2D1/2/3 (Sakata et al., 2007; G. Wu et al., 2003; K. Wu et al., 89 
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2000). A “hand-off” model has been proposed where UBE2D3 transfers the first 90 
ubiquitin to an SCF-bound substrate, followed by poly-ubiquitin chain elongation 91 
catalyzed by the human CDC34 ortholog UBE2R1 or its highly related isoform UBE2R2 92 
(K. Wu et al., 2010). More recently, the E3 enzyme ARIH1 was shown to function with 93 
multiple CRLs in a manner similar to UBE2D3 in both humans (Scott et al., 2016) as 94 
well as in Caenorhabditis elegans (Dove et al., 2017). Despite the apparent requirement 95 
for UBE2D1/2/3 or ARIH1 to initiate a poly-ubiquitin chain on human substrates, 96 
UBE2R1/2 are capable of both priming and poly-ubiquitin chain extension on milli-97 
second time scales in in vitro ubiquitylation assays (Kleiger, Saha, et al., 2009; Pierce et 98 
al., 2009; Saha & Deshaies, 2008). The relative importance of these various 99 
mechanisms in human SCF-mediated poly-ubiquitin chain formation on substrates has 100 
yet to be addressed.  101 
 In this study, we investigate the role of the different chain initiating and elongating 102 
enzymes implicated in human SCF function. We use single reaction monitoring mass 103 
spectrometry to estimate physiological E2 and E3 concentrations in cells, quench flow-104 
based rapid kinetics to analyze the contributions of different enzymes to in vitro 105 
reconstituted reactions, and genetic analysis to uncover functional redundancies 106 
between different SCF-associated factors. These results uncover three main principles. 107 
First, some substrates and/or substrate receptors appear selective for a particular 108 
ubiquitin-modifying enzyme even when assayed at physiological concentrations, 109 
whereas others are more promiscuously ubiquitylated by different ubiquitin-modifying 110 
enzymes. Second, the rates of ubiquitylation can depend dramatically on enzyme 111 
concentrations. In particular, UBE2R2 activity is robust when levels are sufficient to 112 
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saturate the SCF-substrate complex, but virtually undetectable when assayed at 113 
physiological levels. Finally, unlike in yeast, human SCF activity appears to be highly 114 
buffered such that the loss of any single SCF-associated E2 or E3 is compensated for 115 
by redundant factors. We uncover a redundant role for the E2 enzyme UBE2G1 that 116 
explains why loss of both UBE2R1 and UBE2R2 can be tolerated by cells. Collectively 117 
these results illuminate how the SCF regulatory system has been diversified through 118 
evolution and how this diversification has been exploited to allow differential substrate 119 
ubiquitylation. 120 
 121 
  122 
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Results 123 
Intracellular concentrations of SCF-associated enzymes. We sought to resolve how 124 
multiple ubiquitin priming and poly-ubiquitin elongating enzymes collaborate with human 125 
SCF ubiquitin ligases by measuring the individual rates of poly-ubiquitin chain priming 126 
and elongation using pre-steady state kinetic measurements with different combinations 127 
of SCF-associated enzymes. To accomplish this goal, we employed two well-128 
characterized and biologically important SCF complexes based on the βTRCP substrate 129 
receptor (SCFβTRCP) and the FBW7 substrate receptor (SCFFBW7; for more details, 130 
please see Appendix 1).   131 
A critical parameter for measurement of the kinetics of in vitro reconstituted 132 
reactions is the concentrations for both ubiquitin chain initiator and elongator E2s and 133 
E3s needed to saturate the E3–substrate complex and thereby promote maximal rates 134 
of ubiquitin transfer to the substrate. Multi-turnover Michaelis-Menten kinetic assays 135 
were used to determine the levels of ARIH1, UBE2D3 and UBE2R2 necessary to 136 
saturate either SCFβTRCP or SCFFBW7 complexes (Figure 1, Figure 1 - figure supplement 137 
1, and Table 1). Care was also taken to assess the relative activities of the recombinant 138 
enzyme preparations (Ronchi & Haas, 2012) (please see Appendix 2 for a description 139 
and possible impact on interpretation of results).  140 
 A potential caveat with saturating kinetics is that E2 and E3 concentrations in 141 
cells may be insufficient to saturate the E3–substrate complex, resulting in slower rates 142 
of ubiquitin transfer to the substrate in vivo. To address this issue, single reaction 143 
monitoring (SRM) mass spectrometry was used to determine the copy numbers of 144 
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ARIH1, UBE2D1/2/3, UBE2R1/2, as well as the SCF subunits CUL1 and SKP1 in 145 
several common tissue culture cell lines, enabling calculation of the protein 146 
concentration within the cell (Table 2). To account for modest nuclear enrichment 147 
previously shown for UBE2R1 (Kleiger, Hao, et al., 2009), the activities of ARIH1, 148 
UBE2D3 and UBE2R2 were assayed at twice the cellular concentration estimated by 149 
SRM.  150 
Measurement of ARIH1-catalyzed SCF reaction rates at physiological enzyme 151 
concentrations. The rates of ARIH1-catalyzed ubiquitin chain initiation and elongation 152 
were obtained by measuring the pre-steady state kinetics of a single encounter 153 
ubiquitylation reaction containing SCFFBW7, single lysine Cyclin E peptide, and 2.5 M 154 
ARIH1 to saturate the SCF–substrate complex (Figure 2a-c). The rate of chain initiation 155 
was 0.5 sec-1, the second ubiquitin transfer to substrate was only modestly slower (0.2 156 
sec-1), and the rate of the third ubiquitin transfer was 0.08 sec-1 (Table 3). The kinetics 157 
were sufficient to generate products containing up to four ubiquitins on the substrate 158 
modified poly-ubiquitin chain prior to substrate dissociation from SCF (Figure 2b, 3a).  159 
 Reducing the concentration of ARIH1 some 7-fold lower to more physiological 160 
levels resulted in only modest changes to the rates of ubiquitin transfer. The rates of the 161 
first and the second ubiquitin transfers (0.2 sec-1 and 0.1 sec-1, respectively) were only 162 
2-fold slower than in the case where ARIH1 was saturating for SCF, and the rates of the 163 
third ubiquitin transfers were comparable (Table 3). As such, these reactions at lower 164 
ARIH1 levels still generated products with up to four ubiquitins on SCF-bound 165 
substrates (Figure 2d, Figure 2 - figure supplement 1a, and Figure 3a).    166 
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 Assaying ARIH1 with β-Catenin peptide substrate and SCFβTRCP resulted in both 167 
similar kinetics as well as ubiquitylated products compared with the reactions with 168 
Cyclin E peptide and SCFFBW7 (Figures 2e,f and 3b, Figure 2 - figure supplement 1b,c 169 
and Table 3). The rates of chain initiation were comparable when the ARIH1 170 
concentration was 2.5 M or 0.36 M (0.2 sec-1 and 0.1 sec-1, respectively), and the 171 
rates of the second ubiquitin transfers were also similar to those for Cyclin E. Taken 172 
together, these results demonstrate that ARIH1 rapidly initiates a poly-ubiquitin chain on 173 
SCF-bound substrates and is capable of modest chain extension prior to product 174 
dissociation, even at ARIH1 levels that reflected intracellular concentrations. 175 
 UBE2D3-catalyzed SCF reactions exhibit pronounced specificity for 176 
substrate and/or the SCF substrate receptor. The rates of chain initiation and 177 
elongation were measured next for UBE2D3. At a saturating concentration of 10 M, the 178 
rate of chain initiation was 0.1 sec-1 for SCFFBW7 and Cyclin E peptide (Figure 2 - figure 179 
supplement 2a,b and Table 3), 5-fold slower than the same rate catalyzed by ARIH1. 180 
Similar to ARIH1, this rate was only reduced 2-fold when UBE2D3 levels were lowered 181 
to 3.7 M to more accurately reflect cellular levels (Figure 2 - figure supplement 2c,d 182 
and Table 2). However, when 10 M UBE2D3 was assayed with β-Catenin peptide and 183 
SCFβTRCP, the rate of chain initiation (5 sec-1) was far more rapid than with Cyclin E 184 
peptide and SCFFBW7 (Figure 2 - figure supplement 3 and Table 3). Reduction of the 185 
concentration of UBE2D3 by approximately 3-fold to physiological levels had a 186 
negligible effect on the rate of chain initiation. With chain elongation rates between 0.2 187 
sec-1 - 0.5 sec-1, UBE2D3 was also capable of substantial poly-ubiquitin chain assembly 188 
onto β-Catenin substrate, even at reduced levels (Figure 3b). Thus, in contrast with 189 
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ARIH1, UBE2D3 activity is sensitive to either the identity of the substrate and/or the 190 
SCF substrate receptor.  191 
Physiological levels of UBE2R1/2 are too low to achieve substrate priming. When 192 
saturating levels (10 M) of the ubiquitin-conjugating enzyme UBE2R2 was assayed 193 
with both SCFFBW7 and Cyclin E peptide or with SCFβTRCP with β-Catenin peptide, the 194 
rates of chain initiation were highly similar (0.1 sec-1 - 0.2 sec-1, respectively) and 195 
comparable to the rates generated by ARIH1 (Figure 2 - figure supplement 4 and Table 196 
3). Consistent with prior results, the rate of the second ubiquitin transfer was far more 197 
rapid for both substrates and SCF complexes (40 sec-1 and 30 sec-1 to mono-198 
ubiquitylated Cyclin E and β-Catenin peptides, respectively).  The rates of the third 199 
ubiquitin transfers to SCF-bound substrates were also rapid, resulting in very long poly-200 
ubiquitin chains on products (Figure 3), a hallmark of UBE2R1/2-catalyzed ubiquitylation 201 
reactions. 202 
While reactions containing saturating UBE2R2 for SCF added impressively long 203 
poly-ubiquitin chains onto substrate, reduction of the UBE2R2 levels by 20-fold to mimic 204 
cellular conditions resulted in the near elimination of any product for both Cyclin E and 205 
β-Catenin peptide (Figure 2 - figure supplement 5 and Table 3). Indeed, product levels 206 
were so low that we were unable to estimate the rate of poly-ubiquitin chain initiation for 207 
either substrate. This result strongly suggested that UBE2R1/2 are incapable of 208 
mediating substrate ubiquitylation in vivo without the assistance of other SCF-209 
associated enzymes. 210 
Initiation and elongation enzyme mixtures improve reaction kinetics. We then 211 
compared the rates of chain initiation and elongation for reactions containing initiator E2 212 
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or E3 in combination with UBE2R2. Ubiquitylation reactions containing both saturating 213 
ARIH1 (2.5 M) and UBE2R2 (10 M) for SCFFBW7 were performed in the presence of 214 
Cyclin E peptide (Figure 2 - figure supplement 6a,b). The rate of chain initiation was 215 
only 2-fold slower than in comparison with the same reaction containing only ARIH1 216 
(Table 3). Reduction of both ARIH1 (0.36 M) and UBE2R2 (0.5 M) to more 217 
physiological levels did not affect the rate of chain initiation, but the rate of chain 218 
elongation was greatly reduced when compared to the reaction containing saturating 219 
UBE2R2 alone (Figure 2 - figure supplement 6c,d and Table 3). Similar trends in the 220 
rates as well as the effects on poly-ubiquitin chain lengths were observed for β-Catenin 221 
peptide and SCFβTRCP (Figure 2 - figure supplement 7). Nevertheless, the rates of chain 222 
elongation for ARIH1 in the presence of UBE2R2 were significantly faster than for 223 
reactions containing ARIH1 alone, resulting in substrates modified with poly-ubiquitin 224 
chains that were substantially longer than those formed by ARIH1 in the absence of 225 
UBE2R2 (Figure 3b).  These results suggest that while ARIH1 can provide the initiator 226 
ubiquitin for subsequent elongation by UBE2R1/2, it also acts as a competitor for the 227 
elongation cycles in in vitro ubiquitylated reactions.   228 
The rates of chain initiation and elongation were then determined for analogous 229 
reactions containing both 10 M UBE2D3 and UBE2R2 (Figure 2 - figure supplements 8 230 
and 9; Table 3). While the rates of ubiquitin chain initiation were comparable to those 231 
from reactions containing UBE2D3 alone, the rates of the second ubiquitin transfer to 232 
substrate were suppressed compared to reactions containing UBE2R2 alone, in 233 
particular for reactions with β-Catenin peptide and SCFβTRCP (0.9 sec-1 versus 30 sec-1, 234 
respectively). Reduction of the levels of both UBE2D3 (3.7 M) and UBE2R2 (0.5 M) 235 
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further slowed the rates of chain elongation; however, long poly-ubiquitin chains were 236 
still observed on substrates, especially β-Catenin peptide (Figure 3). These results 237 
suggested that, like ARIH1, UBE2D3 also acts as a competitor for chain elongation by 238 
UBE2R1/2.  239 
Physiological concentrations appear optimized for substrate ubiquitylation. 240 
Considering that the average estimated physiological concentrations for ARIH1, 241 
UBE2D3, and UBE2R1/2 (Table 2) were all quite close to the Km values of these 242 
enzymes for SCF (Table 1), we reasoned that relatively subtle changes in ARIH1, 243 
UBE2D3, and UBE2R1/2 levels may result in substantial differences in both the fraction 244 
of substrate converted into ubiquitylated product as well as the lengths of the poly-245 
ubiquitin chains. To test for this, single encounter ubiquitylation reactions were 246 
assembled with SCFFBW7, Cyclin E peptide, and where ARIH1, UBE2D3, and UBE2R2 247 
levels were assayed either up to 4 times higher or lower than their estimated 248 
physiological concentrations.  249 
 Very little product was observed for any of the reactions when the enzyme levels 250 
were assayed at either one-fourth or one-half the estimated cellular concentrations 251 
(Figure 4). Substantial mono-ubiquitylation of Cyclin E peptide occurred for both ARIH1 252 
and UBE2D3 when assayed at the estimated physiological concentrations, and 253 
introduction of UBE2R2 to these reactions also resulted in the formation of poly-254 
ubiquitin chains onto product containing 4 or more ubiquitins (Figure 4 and Figure 4 - 255 
figure supplement 1). Increasing ARIH1 levels to either twice or four times the estimated 256 
cellular concentration resulted in both increased conversion of substrate to product 257 
containing at least one ubiquitin, as well as substantial poly-ubiquitin chains on product 258 
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(up to 5 ubiquitins in the latter case). Increasing UBE2D3 levels also resulted in greater 259 
product formation, although to a lesser extent than for ARIH1. The UBE2D3 product 260 
was also primarily mono-ubiquitylated. Increasing the UBE2R2 concentration also led to 261 
some product formation, all containing very long poly-ubiquitin chains. Finally, 262 
combining either ARIH1 or UBE2D3 with UBE2R2 and assaying at levels two or four 263 
times greater than the estimated physiological levels resulted in greater amounts of 264 
product containing much longer poly-ubiquitin chains. Thus, subtle changes in the 265 
concentrations of ARIH1, UBE2D3, and UBE2R2 led to significant changes in both the 266 
amount of substrate converted to product as well as the lengths of the poly-ubiquitin 267 
chains on the product.   268 
UBE2R1/2 activity is dispensable for the degradation of four canonical SCF 269 
substrates. Since modest changes in enzyme levels, particularly UBE2R2, resulted in 270 
substantial changes in poly-ubiquitin chains appended to substrate, we reasoned that a 271 
2-fold reduction in UBE2R1/2 levels might result in the stabilization of SCF substrates in 272 
the cell. Surprisingly, the stabilities of the SCFFBW7 substrates p27 and CYCLIN E were 273 
comparable by cycloheximide chase in either wild-type (WT) or UBE2R1 knock out 274 
HEK293T Flp-In T-Rex (293T-FiTx cells; Figure 5 - figure supplement 1a). Note that 275 
ablation of UBE2R1 protein did not significantly affect UBE2R2 mRNA levels, ruling out 276 
a dosage compensation effect (Figure 5 - figure supplement 1b).  277 
 Since the above results may be reconciled by the presence of UBE2R2 protein 278 
that may compensate for loss of UBE2R1 protein, CRISPR-Cas9 technology was used 279 
to disrupt both UBE2R1 and UBE2R2 loci in HEK 293T cells. Multiple clones were 280 
isolated that contained frameshift indels that caused total ablation of UBE2R1 and/or 281 
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UBE2R2 protein, as demonstrated by Western blotting with antibodies with high 282 
specificity to either UBE2R1 or UBE2R2 (Figure 5 - figure supplements 2 and 6b). 283 
Remarkably, the steady state levels of three SCF substrates, -CATENIN, CYCLIN E, 284 
and p27, were not significantly enriched in three independent UBE2R1/2 knockout cell 285 
lines in comparison with 3 control lines (Figure 5a,b). Cycloheximide chase analysis 286 
performed on the UBE2R1/2 double knockout cells demonstrated that p27 protein 287 
degradation was indistinguishable in comparison with control cells (Figure 5c and Figure 288 
5 - figure supplement 3a). The degradation of IBα in response to TNFα treatment for 289 
control or UBE2R1/2 double knockout cells also resulted in indistinguishable rates of 290 
degradation (Figure 5d and Figure 5 - figure supplement 3b). Finally, since Cdc34 is 291 
required for the G1-S cell cycle transition in budding yeast, flow cytometry was used to 292 
estimate the percentage of cells in each phase of the cell cycle in control versus 293 
UBE2R1/2 double knockout cells but found no differences (Figure 5e and Figure 5 - 294 
figure supplement 4). These results demonstrate that both UBE2R1 and UBE2R2 are 295 
entirely dispensable for the degradation of at least some SCF substrates and 296 
progression through the cell cycle.  297 
A genome-wide CRISPR screen reveals specific dependency of UBE2R1/ UBE2R2 298 
double knockout cells on UBE2G1. To explain how p27, CYCLIN E, β-CATENIN, and 299 
IBα become ubiquitylated in the absence of UBE2R1/2, we considered two potential 300 
hypotheses: (1) ARIH1 and/or UBE2D1/2/3 are sufficient for both initiation as well as 301 
modest poly-ubiquitin chain elongation (as evidenced by the kinetic results here); and 302 
(2) a different E2 may complement UBE2R1/2 activity in the cell. The first hypothesis 303 
predicts that ARIH1 and/or UBE2D1/2/3 might become more essential in the absence of 304 
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UBE2R1/2, whereas the second hypothesis suggests that one or more other E2s may 305 
become essential in the absence of UBE2R1/2.  306 
To address this question in an unbiased manner, we performed genome-wide 307 
CRISPR knockout screens in the NALM-6 pre-B cell lymphoma line with the previously 308 
reported EKO sgRNA library (Bertomeu et al., 2018) to identify genes that exhibit 309 
synthetic lethality with the loss of UBE2R1 and/or UBE2R2. Cell populations were first 310 
transduced with individual sgRNAs targeting either UBE2R1, UBE2R2, or both UBE2R1 311 
and UBE2R2, as well as the AAVS1 locus and a non-targeting control sgRNA (Figure 312 
6a and Figure 6 - figure supplement 1; for screen details, see Materials and Methods). 313 
Each population was transduced with the library pool and propagated for 14 days, 314 
followed by determination of sgRNA frequencies by next generation sequencing and 315 
generation of gene-level scores by the RANKS algorithm (Bertomeu et al., 2018).  316 
Differential RANKS scores for every gene in each experimental screen were obtained 317 
by subtraction of the averaged RANKS scores of the two control screens. Strikingly, the 318 
UBE2G1 gene scored as the top synthetic lethal interactor in both replicates of the 319 
UBE2R1/2 double knockout screen but did not score in either of the UBE2R1 or 320 
UBE2R2 single knockout screens (Figure 6b-e). Moreover, out of the 5 experimental 321 
screens analyzed, the only statistically significant hit (FDR<0.05) was UBE2G1 in the 322 
UBE2R1/2 double knockout screen. The three-way genetic interaction between 323 
UBE2R1, UBE2R2 and UBE2G1 was validated by population-level knockout of 324 
UBE2G1 in UBE2R1/2 single and double knockout clones in the NALM-6 parental cell 325 
line (Figure 6 - figure supplement 2). We did not observe any other significant genetic 326 
interactions with loss of UBE2R1/2, including with ARIH1, UBE2D3 or other SCF 327 
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components. These genetic screen data suggested that UBE2G1 uniquely buffers the 328 
loss of UBE2R1/2, and in particular that the elongation activity of ARIH1 and UBE2D3 329 
are unable to substitute for the three dedicated elongation E2 enzymes.   330 
UBE2G1 mediates SCF substrate instability in vivo and exhibits potent chain 331 
elongation activity in vitro. To determine whether depletion of UBE2G1 may affect the 332 
stability of SCF substrates, UBE2R1/2 double knockout 293T cell lines were treated 333 
with siRNAs targeting UBE2G1. p27 levels were modestly increased in populations 334 
treated with non-targeting siRNAs but were strongly increased in UBE2R1/2 double 335 
knockout cells treated with UBE2G1-targeting siRNA (Figure 7a,b). Stabilization of 336 
CYCLIN E protein was also observed in UBE2R1/2 double knockout cells treated with 337 
UBE2G1-targeting siRNA.  To determine whether these observations might extend to 338 
additional CRLs, we assessed the CRL2VHL substrate HIF1 in control versus 339 
UBE2R1/2 knockout cell lines. Similar to p27, HIF1 was heavily stabilized upon 340 
knockdown of UBE2G1 in UBE2R1/2 double knockout cells (Figure 7a,b). These results 341 
demonstrate the functional redundancy between UBE2R1/2 and UBE2G1 across the 342 
CRL family. 343 
 We then determined whether UBE2G1 can support SCF-mediated substrate 344 
ubiquitylation in vitro. UBE2G1 itself had no measurable chain initiation activity, but 345 
exhibited substantial chain elongation activity against either mono-ubiquitylated β-346 
Catenin or Cyclin E peptides in the presence of SCFFBW7 or SCFβTRCP, respectively 347 
(Figure 7 - figure supplement 1a).  The Km of UBE2G1 was estimated as 1.30 ± 0.2 μM 348 
from multi-turnover Michaelis-Menten kinetics in the presence of mono-ubiquitylated 349 
Cyclin E peptide substrate (Figure 7 - figure supplement 1b,c and Table 1). We then 350 
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tested the ability of UBE2G1 to participate in a hand-off reaction with either ARIH1 or 351 
UBE2D3. Maximal chain elongation on substrate was observed only when ARIH1 or 352 
UBE2D3 were assayed in the presence of UBE2G1 (Figure 7c,d). Finally, the pre-353 
steady state kinetics of UBE2G1-catalyzled ubiquitin transfer to the Cyclin E peptide 354 
yielded rates of ubiquitin transfer of 1 ± 0.1 sec-1 under conditions where UBE2G1 levels 355 
were sufficient to saturate SCF (Figure 7e, Figure 7 - figure supplement 1d, and Table 356 
3). In terms of enzyme efficiency (kobs/Km), the UBE2R2 efficiency (1.3x10
8 M-1 sec-1) 357 
was 173-fold greater than for UBE2G1 (7.7x105 M-1 sec-1) for the first ubiquitin transfer 358 
to mono-ubiquitylated substrate, and 17-fold greater for the subsequent transfer. Thus, 359 
while UBE2R2 is far more efficient during catalysis of ubiquitin transfer to substrate on 360 
SCF, UBE2G1 activity is nevertheless sufficient to poly-ubiquitylate substrates that have 361 
been primed by either UBE2D1/2/3 or ARIH1. Collectively, these results demonstrate 362 
that UBE2G1 can act as a dedicated elongation E2 for SCF complexes, and thereby 363 
buffer cells against the loss of UBE2R1 and UBE2R2.  364 
Discussion 365 
Our studies using in vitro enzyme kinetics and genetic approaches have 366 
uncovered new complexities in the mechanism of poly-ubiquitin chain initiation and 367 
elongation by human SCF ubiquitin ligases. First, comparison of the ARIH1- or 368 
UBE2D3-catalyzed ubiquitin chain initiation demonstrates that the rates are not 369 
substantially affected by enzyme concentrations that range from physiological to 370 
saturating levels. Second, while the rates of ubiquitin chain initiation by UBE2R2 when 371 
saturating for SCF are comparable to those of ARIH1 and UBE2D3, at physiological 372 
levels UBE2R2 clearly cannot support ubiquitin chain initiation or ubiquitylated product 373 
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formation. Third, the rate of chain initiation by UBE2D3 for β-Catenin peptide and 374 
SCFβTRCP is some 50-fold faster than for reactions containing SCFFBW7 and Cyclin E 375 
peptide, indicating that UBE2D3 has a strong preference for some substrates and/or 376 
substrate receptors. Finally, UBE2R1/2 function is genetically buffered by UBE2G1, 377 
such that loss of UBE2R1/2 does not cause overt proliferation defects in cell line models, 378 
whereas the simultaneous loss of all three E2s leads to inviability. Consistently, 379 
UBE2G1 supports chain elongation activity against primed mono-ubiquitylated 380 
substrates in vitro.  381 
 Our results suggest that human SCF-catalyzed substrate ubiquitylation has 382 
evolved additional regulatory layers compared to the simpler yeast SCF system (Figure 383 
8). In S. cerevisiae, Cdc34 appears both necessary and sufficient for SCF function since 384 
Ubc4/5 (the UBE2D1/2/3 orthologs) have no in vitro activity with reconstituted yeast 385 
SCF and cannot compensate for the loss of CDC34 in cells. While it is surprising that 386 
Cdc34 homologs UBE2R1 and UBE2R2 appear to be dispensable in human cell lines, 387 
this difference may in part be explained by the respective concentrations of Cdc34 and 388 
UBE2R1/2 in yeast versus human cells. The concentration of Cdc34 in the yeast 389 
nucleus has been estimated at approximately 10 M and 2- to 3-fold lower in the 390 
cytoplasm (Kleiger, Hao, et al., 2009). Based on the kinetic results here, these levels 391 
would be sufficient for robust chain initiation and elongation. In contrast, UBE2R1/2 392 
protein levels in several human cell lines are at least an order of magnitude lower than 393 
in yeast, and well-below the low micromolar value of the Km of UBE2R2 for SCF bound 394 
to an unmodified substrate (Table 1). On the other hand, the Km of UBE2R2 for SCF 395 
bound to a mono-ubiquitylated substrate is approximately 0.3 M, similar to the 396 
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physiological concentration of UBE2R1/2 in tissue culture cells, thus explaining why 397 
UBE2R1/2 is still able to promote chain elongation on primed substrate in vitro.  398 
 A possible exception to this interpretation may be our observation that a fraction 399 
of UBE2R1 is concentrated into foci in which protein levels may be higher (Figure 5 - 400 
figure supplement 5), and thus potentially capable of initiating localized ubiquitylation 401 
reactions with CRL ligases. Multiple E3s contain sequence motifs that may drive the 402 
formation of membraneless organelles such as nuclear speckles and Cajal bodies 403 
(Hughes et al., 2018). In particular, the CUL3 substrate receptor SPOP forms such 404 
structures in cells in the presence of its substrates (Bouchard et al., 2018). Additional 405 
experiments are necessary to determine whether SCF or other CRLs and their 406 
substrates are co-located within UBE2R1 foci, and whether UBE2R2 or UBE2G1 also 407 
form foci. 408 
 Our genome-wide genetic screen suggests that CRL function is more buffered in 409 
human cells compared to yeast. Aside from UBE2G1, at least at the level of resolution 410 
of our screen, we detected no other significant genetic interactions with loss of 411 
UBE2R1/2, including ARIH1 and UBE2D3. This result implies that the elongation activity 412 
of ARIH1 and UBE2D3 are insufficient to compensate for the combined loss of 413 
UBE2R1/2 and UBE2G1. In contrast, conditional alleles of CDC34 exhibit many dozens 414 
of well-documented synthetic lethal interactions in yeast (Oughtred et al., 2019). We 415 
note that while the UBE2R1/2 double mutant is viable in two different transformed cell 416 
lines, UBE2R1/2 function may still be essential or at least important in other cell lines. 417 
For instance, the reduction of UBE2R1 protein levels in U2OS cells resulted in partial 418 
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stabilization of IKB (K. Wu et al., 2010) and UBE2R1/2 function may still be required in 419 
an organismal context, an issue that remains to be addressed.  420 
 Why did SCF-catalyzed substrate ubiquitylation evolve separate chain initiating 421 
versus elongating enzymes, and why are multiple initiators and elongating E2s 422 
necessary? One likely reason is that this separation of function affords additional 423 
opportunities to diversify the control of SCF ligase activity. For instance, since ARIH1 is 424 
active only in the presence of neddylated CRL complexes, and SCF complexes tend to 425 
be activated only when bound to substrate (Emberley et al., 2012; Enchev et al., 2012; 426 
Fischer et al., 2011; Pierce et al., 2013), ARIH1 activity is held in check unless it is in 427 
the presence of activated SCFs. At least in vitro, saturating levels of UBE2R1/2 have 428 
substantial activity with un-neddylated SCF, such that the ARIH1-catalyzed hand-off 429 
mechanism may prevent unwanted auto-ubiquitylation of E3s not bound to substrate. A 430 
further layer of control appears to lie at the poly-ubiquitin chain initiation step, based on 431 
E2 specificity for particular substrates and/or substrate receptors. Thus, while UBE2D3 432 
was less efficient than ARIH1 at chain initiation onto Cyclin E peptide substrate, the rate 433 
of the first ubiquitin transfer to β-Catenin peptide (5 sec-1) was 50-fold greater than with 434 
Cyclin E peptide, and 25-fold faster than ARIH1 for the same reaction. This effect may 435 
be explained by the affinity of the E2-E3 interaction and competition between different 436 
initiating enzymes. For instance, we observed that the Km of UBE2D3 for SCF
FBW7 is 437 
significantly higher than for SCFβTRCP. Similarly, ARIH1 but not UBE2D3 supports in 438 
vitro ubiquitylation of CRY1 bound to SCFFbxL3 (Scott et al., 2016). The use of multiple 439 
E2s and initiating enzymes evidently allows more elaborate specificity across the SCF 440 
substrate repertoire.  441 
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 The slower ubiquitin transfer rate of UBE2G1 compared to UBE2R1/2, and the 442 
weak elongation activity of ARIH1 and UBE2D3 may have biological relevance. For 443 
instance, delayed substrate ubiquitylation and degradation is important during mitotic 444 
exit in yeast (Rape et al., 2006) and in addition the proteasome is capable of 445 
recognizing substrates modified by different chain lengths and/or on different lysine 446 
residues (Y. Lu et al., 2015). Whether such effects are important for UBE2G1-mediated 447 
degradation of particular CRL substrates remains to be determined.  448 
Finally, the combinatorial plasticity of SCF chain initiation and elongation 449 
reactions may have important practical considerations in drug discovery. Recently, 450 
bivalent small molecule ligands (variously referred to as PROTACS, IMiDs, or 451 
SNIPERs) have been developed to target non-cognate substrates to E3 enzymes, and 452 
thereby eliminate proteins that contribute to tumorigenesis and other disease states 453 
(Paiva & Crews, 2019). This promising E3-based therapeutic approach, termed event-454 
driven pharmacology (Lai & Crews, 2017), will be enabled by a more precise 455 
understanding of E3 catalytic mechanisms (Scudellari, 2019). To date, bivalent or 456 
"molecular glue" type ligands have been developed for several CRL complexes 457 
including scaffolds that direct neo-substrates to the CUL4CRBN, CUL4DCAF15, CUL2VHL 458 
and CUL3KEAP1 enzymes (Paiva & Crews, 2019). It seems likely that particular 459 
combinations of chain initiating and elongating enzymes will preferentially modify neo-460 
substrates in a context-specific fashion.  For example, UBE2G1 has recently been 461 
shown to mediate chain elongation of neomorphic substrates that are bridged to 462 
CRL4CRBN by thalidomide analogs (G. Lu et al., 2018; Patil et al., 2019; Sievers et al., 463 
2018).  464 
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Many other details remain to be elucidated regarding how SCF and other CRLs 465 
function with a suite of ubiquitin-modifying enzymes. Do different combinations of 466 
ARIH1 or UBE2D3 with UBE2R1/2 or UBE2G1 produce different products that alter the 467 
kinetics of substrate degradation? What is the structural basis that underpins initiation 468 
versus elongation activities? How do the localized dynamics of E2, ARIH1 and SCF 469 
interactions in vivo relate to function? Are there yet additional E2s or E3s that can also 470 
function with CRLs under different circumstances? Answers to these questions will 471 
further our understanding of this important and fascinating enzyme system. 472 
  473 
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Materials and Methods 474 
Cell lines. HEK293T Flp-In T-Rex (293T-FiTx) HEK293T/17, HeLa, and MRC5 cells 475 
were all grown in DMEM (4.5 g/L glucose) supplemented with 10 % fetal bovine serum, 476 
4 mM L-Glutamine, 100 units/mL Penicillin, 100 g/mL Streptomycin, and 10 g/mL 477 
Ciprofloxacin in a standard tissue culture incubator with 5 % carbon dioxide. NALM-6 478 
cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. 479 
 The NALM-6 cell line was provided by Stephen Elledge (Harvard Medical 480 
School). Authenticity was determined by whole genome sequence analysis of the 481 
parental line and the doxycycline inducible Cas9 clone used for CRISPR screens. Both 482 
cell lines matched the previously reported NALM-6 sequence and chromosome 483 
complement. Both lines were verified as mycoplasma negative before experiments were 484 
initiated. All other cell lines were purchased directly from the ATCC (see Supplementary 485 
File 1 - key resources table) prior to beginning these experiments, and were grown in 486 
the presence of Ciprofloxacin to eliminate potential mycoplasma contamination.  487 
Constructs. All expression constructs used in this study have been listed in the key 488 
resources table (Supplementary File 1). Expression constructs that had been generated 489 
specifically for this study include human (His)8-NEDD8, human (His)6-ubiquitin, (His)6-no 490 
lysine (K0) human ubiquitin, and UBE2G1. 491 
Protein Expression and Purification. Detailed protocols for the expression and 492 
purification of split-n-co-express human K720R and neddylated CUL1-Rbx1 (Li et al., 493 
2005), full-length human βTRCP2 (FBW11)-SKP1 complex (Scott et al., 2016), human 494 
FBW7(263-C-terminus)-SKP1 complex (Scott et al., 2016), human UBE2L3 and ARIH1 495 
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(Scott et al., 2016), UBE2R2 (Hill et al., 2018), UBE2D3 (Hill et al., 2018), human 496 
APPBP1-UBA3, human UBC12 (Huang et al., 2005), human UBE1 (E1) (Scott et al., 497 
2016), and mono-ubiquitylated β-Catenin peptide (Hill et al., 2018) have been described 498 
in detail elsewhere.  499 
 The (His)8-NEDD8 construct was synthesized by Integrated DNA Technologies 500 
and cloned into pET-11b. The vector was transformed into Rosetta(DE3) cells and 501 
cultured in LB medium containing 10 g/L dextrose at 37° C. Bacterial cells were 502 
collected by centrifugation at 5,000 x g for 10 minutes and the media exchanged for LB 503 
without dextrose just prior to induction of protein expression with 0.4 mM IPTG at 24° C 504 
for 4 hours. Cells were harvested by centrifugation at 5,000 x g for 10 minutes, and the 505 
cell pellets washed in 1x PBS prior to drop-freezing in liquid nitrogen and storage at -80° 506 
C. The cells were lysed by sonication in nickel wash buffer containing 30 mM Tris-HCl 507 
(pH 7.5), 250 mM NaCl, 20 mM imidazole, 1 mM β-mercaptoethanol, 5% glycerol, and 508 
1% Triton X-100. Lysates were centrifuged at 21,000 x g for 1 hour and incubated with 509 
Ni-NTA agarose resin for 1 hour with gentle rotation. The resin was washed several 510 
times with standard nickel wash buffer, followed by elution in buffer containing 300 mM 511 
imidazole, 200 mM NaCl, and 50 mM Na-HEPES (pH 8.0). The eluate was then spin 512 
filtered and immediately loaded onto a Superdex 75 gel filtration column that had been 513 
pre-equilibrated in storage buffer containing 30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 514 
and 10% glycerol. Note that the eluate should not be concentrated prior to gel filtration 515 
to avoid protein precipitation. All fractions containing NEDD8 protein were combined, 516 
concentrated to approximately 200 μM, and sub-aliquoted into single-use volumes 517 
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before drop-freezing in liquid nitrogen and long-term storage at -80° C. Typical protein 518 
yield was 0.5 mg per 1L of cell culture. The calculated extinction coefficient is  519 
2,560 M-1cm-1. 520 
 The (His)6-ubiquitin construct was synthesized by IDT and cloned into pET-11b. 521 
Following transformation of the plasmid into the Rosetta(DE3) bacterial strain, cells 522 
were cultured in LB medium containing 10 g/L dextrose at 37° C, followed by 523 
centrifugation at 5,000 x g for 10 minutes to exchange the media for LB lacking dextrose. 524 
Protein expression was then induced by adding 0.4 mM IPTG followed by incubation at 525 
30° C for 4 hours. Cells were harvested as described above for NEDD8 protein. To 526 
initiate protein purification, the cell pellets were first lysed in nickel wash buffer 527 
containing 30 mM Tris-HCl (pH 7.5), 250 mM NaCl, 20 mM imidazole, 5% glycerol, and 528 
0.1% IGEPAL. Lysates were centrifuged at 21,000 x g for 1 hour, the precipitates 529 
discarded, and the lysates incubated with Ni-NTA agarose resin for 1 hour and gentle 530 
rotation. The resin was washed several times with standard nickel wash buffer, followed 531 
by elution in buffer containing 300 mM imidazole, 200 mM NaCl, and 50mM Na-HEPES 532 
(pH 8.0). The eluate was then concentrated, spin filtered, and subjected to gel filtration 533 
on a Superdex 75 column buffered in storage buffer (see above). Typical protein yield 534 
was 6 mg per 1L of cultured cells. The calculated extinction coefficient is 1,280 M-1cm-1. 535 
 A plasmid for TEV protease expression was purchased from Addgene (Plasmid 536 
#8827). Bacterial cells were grown as described (Tropea et al., 2009). The cell pellets 537 
were lysed by sonication in buffer containing 50mM sodium phosphate (pH 8.0), 200 538 
mM NaCl, 10% glycerol, and 25 mM imidazole. Lysates were centrifuged at 21,000 x g 539 
for 1 hour and incubated on Ni-NTA agarose resin for 1 hour with gentle rotation. The 540 
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resin was washed several times with lysis buffer, then eluted in a buffer containing 30 541 
mM Tris-HCl (pH 8.0), 300 mM imidazole, 200 mM NaCl, and 10% glycerol. After elution, 542 
1 mM EDTA and 5 mM DTT were added to the eluate, which was then concentrated, 543 
spin filtered, and subjected to gel filtration on a Superdex 75 column that had been pre-544 
equilibrated in storage buffer. Typical protein yield is 0.5mg per 1L of lysed cells. The 545 
calculated extinction coefficient is 32,290 M-1cm-1. 546 
 The (His)6-K0-ubiquitin construct was synthesized by IDT with the amino acid 547 
sequence for human ubiquitin. It was cloned into pET-11b, and expressed and purified 548 
in an identical manner as (His)6-ubiquitin (see above). Typical protein yield was 3 mg 549 
per 1L of cell culture. The calculated extinction coefficient is 1,280 M-1cm-1. 550 
 An expression construct for UBE2G1 was first obtained from Addgene (Plasmid 551 
#15790), and then sub-cloned into pGEX-4T1 including a TEV protease cleavage site 552 
between GST and the UBE2G1 N-terminus. Expression and purification were carried 553 
out identically to that of UBE2D3 (as above). Typical protein yield was 1 mg per 1L of 554 
cell culture. The calculated extinction coefficient used was 29,500 M-1cm-1. 555 
 Mono-ubiquitylated Cyclin E peptide substrate was generated by incubating 130 556 
μM (His)6-ubiquitin, 0.25 μM human E1, 2 μM UBE2D3, 600 nM K720R Cul1-Rbx1, 600 557 
nM FBW7(263-C-terminus)-Skp1 complex, and 100 μM cyclin E peptide overnight at 558 
20° C. The reaction was quenched the following morning by addition of DTT to a final 559 
concentration of 10 mM DTT, and product was isolated by three successive rounds of 560 
gel filtration on a Superdex 75 column that had been pre-equilibrated in storage buffer. 561 
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The yield of purified mono-ubiquitylated Cyclin E peptide was approximately 5% of the 562 
starting peptide. The calculated extinction coefficient is 2,560 M-1cm-1. 563 
Multi-turnover reactions for estimation of KM. Reactions were setup by first adding 564 
E1 to a mixture already containing reaction buffer (30 mM Tris-HCl (pH 7.5), 100 mM 565 
NaCl, 5 mM MgCl2, 2 mM DTT and 2 mM ATP) and ubiquitin and incubating for 1 566 
minute (see Supplementary File 2 for concentrations). The mixture was then divided into 567 
ten individual Eppendorf tubes, followed by the addition of a 2-fold dilution series of 568 
ARIH1 (UBE2L3 was kept constant for all reaction in the titration series and was always 569 
in excess of ARIH1), UBE2D3, Ube2R2, or UBE2G1. After 2 minutes of incubation, 570 
SCFβTRCP or SCFFBW7 complexes were added, centrifuged briefly, and then initiated by 571 
addition of 32P-labeled β-catenin or Cyclin E peptide substrate (unmodified or mono-572 
ubiquitylated). Reactions were quenched in 2x SDS-PAGE buffer (100 mM Tris-HCl (pH 573 
6.8), 20 % glycerol, 30 mM EDTA, 4 % SDS, and 4 % beta-mercaptoethanol), ensuring 574 
that reactions containing the highest concentration of E2 or ARIH1 had converted no 575 
more than 20% of substrate into product. Each reaction was performed in duplicate, and 576 
time points were resolved on 18% polyacrylamide SDS-PAGE gels. Autoradiography 577 
was performed using a Typhoon 9410 Imager and Image Quant software (GE 578 
Healthcare). Percent conversion was determined by dividing the total product signal (e.g. 579 
any band that migrated slower than substrate) by the entire lane signal, and then 580 
estimating the velocity by first normalizing for substrate and enzyme concentrations 581 
(multiplying by substrate concentration and dividing by the SCF concentration) and then 582 
dividing by the time of incubation. The data were fit to the Michaelis-Menten equation, 583 
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𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =  
𝑘𝑐𝑎𝑡[𝑆]
([𝐾𝑀 + [𝑆])
 , where [S] represents the substrate concentration and KM is the 584 
Michaelis constant, using nonlinear curve fitting (Prism 8).  585 
Estimation of cellular protein concentrations using SILAC SRM (Selected 586 
Reaction Monitoring) mass spectrometry. HEK 293T/17, 293T-FiTx, HeLa or MRC5 587 
cells were grown in isotopically heavy (R6 and K8) SILAC medium for a minimum period 588 
of 10-cell doublings. Cells were harvested from 10 cm dishes, resuspended in 1 ml PBS, 589 
filtered through 40 µm mesh and counted using a CEDEX HiRES automated cell 590 
counter (Roche), which determines average cell number and cell diameter from 20 591 
technical replicates. Cells were lysed in 500 µl of lysis buffer (8 M Urea, 100 mM 592 
ammonium bicarbonate, 5 mM TCEP) that was spiked with a master mix of purified 593 
recombinant proteins (ARIH1, UBE2D3, UBE2R1, UBE2R2, CUL1 and SKP1; for 594 
concentrations and details see Table 2 - source data 1). Lysates were then sonicated 595 
for 30 sec (1 sec on/off) at 30 % maximum efficiency on a Branson Sonifier and 596 
subsequently incubated at 23° C for 20 minutes. Lysates were then clarified by 597 
centrifugation at 26,000 x g for 10 minutes and the protein concentration was 598 
determined via A280 on a nanodrop instrument. Subsequently, 100 µg of total protein 599 
were alkylated via iodoacetamide followed by digest for 4 hours at 1 µg/30 µg LysC and 600 
o/n at 1 µg/30 µg trypsin at 23C and 550 rpm in a temperature-controlled shaker. The 601 
digested samples were acidified with 50% formic acid (final concentration 5%), diluted 602 
1:1 in 0.2% formic acid and then desalted using C18 cartridges (SPE 50 mg/1ml C18 603 
Hypersep column Thermo #60108-390). C18 eluates were lyophilized and resuspended 604 
in 2% Acetonitrile and 0.2% formic acid Buffer A and approximately 300ng of total 605 
peptide were subjected to SRM MS analysis on a QTRAP 6500 (SCIEX) under 606 
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conditions previously described in Reitsma et al. (Reitsma et al., 2017). Data was 607 
analyzed using Skyline (MacLean et al., 2010), RStudio, and Excel. The obtained heavy 608 
to light ratios were used to calculate estimates of cellular concentrations (for details, see 609 
Table 2 - source data 1). 610 
Pre-steady state single-encounter quench flow reactions. Reactions were 611 
assembled in two separate mixtures: an E1/E2 mix that contained excess unlabeled 612 
peptide (tube 1) and an SCF-32P-labeled substrate mix (tube 2; see Supplementary File 613 
2 for concentrations). Following addition of E2 and/or ARIH1 to tube 1 already 614 
containing reaction buffer (30 mM Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM MgCl2, 2 mM 615 
DTT and 2 mM ATP) and ubiquitin, each mix was incubated for at least 8 minutes while 616 
being loaded into separate sample loops on a KinTek RQF-3 quench flow instrument. 617 
Reactions were initiated by bringing the two mixes together in drive buffer (30 mM Tris-618 
HCl (pH 7.5), 100 mM NaCl), and then quenched at various time points in reducing 2x 619 
SDS-PAGE loading buffer (100 mM Tris-HCl (pH 6.8), 20 % glycerol, 30 mM EDTA, 4 % 620 
SDS, and 4 % beta-mercaptoethanol). Each reaction was performed at least in 621 
duplicate, and time points were resolved on 18% polyacrylamide SDS-PAGE gels. 622 
Autoradiography was performed using a Typhoon 9410 Imager and Image Quant 623 
software (GE Healthcare). Each product band was quantified as a fraction of the total 624 
signal of its respective lane. The rates of ubiquitin transfer were determined by fitting to 625 
analytical closed-form solutions (Pierce et al., 2009) using Mathematica. 626 
Single-encounter reactions near estimated physiological concentrations. 627 
Reactions were assembled identically to those for the pre-steady state reactions (see 628 
Supplementary File 2 for the concentrations of the reaction constituents). After an 8 629 
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minute incubation, the E1/E2 mix was pipetted into the SCF/substrate mix initiating the 630 
reaction, which was then briefly vortexed and quenched in reducing 2x loading SDS-631 
PAGE buffer after 10 seconds. The reactions were performed in duplicate, and resolved 632 
and quantified in the same manner as the quench flow reactions above.  633 
Generation of UBE2R1 knockout using CRISPR Cas9 technology. WT 293T-FiTx 634 
cells were seeded onto 6-well tissue culture plates to 80% confluency, and then 635 
transfected with 0.5 g of a pX330 vector containing a small guide sequence targeting 636 
exon 2 of UBE2R1 as well as single stranded DNA oligos (Supplementary File 1) using 637 
Lipofectamine 3000. The DNA oligo contained homology arms adjacent to the predicted 638 
Cas9 cut site as well as a 50 base pair insert that disrupts protein translation by the 639 
introduction of 4 stop consecutive stop codons into the UBE2R1 reading frame. After 48 640 
hours, detached cells were removed by washing with DPBS, followed by treatment of 641 
the attached cells with trypsin solution. Detached cells were diluted in growth media, 642 
counted and diluted to obtain single cells in each well of a 96-well plate. After 1 week, 643 
each well was observed under a microscope to verify single colony formation. After 2 644 
weeks, colonies were exposed to trypsin, and half of the cells were used to seed wells 645 
in a 48-well plate, whereas the other half were lysed using QuickExtract solution. 646 
Genomic DNA was used in PCR reactions with primers adjacent to the PAM site 647 
(Supplementary File 1) that were analyzed by standard agarose gel electrophoresis and 648 
product visualization by staining with ethidium bromide. Incorporation of the oligo into 649 
the genome should result in an increase of PCR product sizes by 50 base pairs (Figure 650 
5 - supplementary figure 6a). Additional PCR primers were generated that also 651 
contained restriction sites which allowed for cloning of the PCR product into pGex 4T-1 652 
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vector and DNA sequencing to confirm correct incorporation of the oligo sequence into 653 
the genomic one. Disruption of UBE2R1 protein expression was also verified by 654 
immunofluorescence microscopy (Figure 5 - supplementary figure 5). 655 
Cycloheximide chase to determine the stabilities of p27 and CYCLIN E proteins. 656 
WT or Ube2R1 knockout 293T-FiTx cells were seeded onto 6-well tissue culture plates 657 
with approximately 0.5 x106 cells per well. Within 24 hours, the growth media was 658 
removed, the cells were washed once with DPBS, and fresh grown media containing 659 
100 g/mL cycloheximide was added. At each time-point, cells were washed once with 660 
DPBS, followed by preparation of lysate by the introduction of 50 - 100 L RIPA buffer 661 
and extraction of the cells from the plate. The lysates were briefly sonicated followed by 662 
centrifugation. A small sample of lysate was withdrawn for estimation of the amount of 663 
protein in each sample by the BCA assay (Thermo Fisher Scientific), followed by the 664 
addition of an equal volume of 2x SDS-PAGE loading buffer (100 mM Tris-HCl (pH 6.8), 665 
20 % glycerol, 30 mM EDTA, 4 % SDS, and 4 % beta-mercaptoethanol). Equal amounts 666 
of lysate were loaded onto 4-20 % Tris-Glycine SDS-PAGE gels and subject to 667 
electrophoresis. Denatured proteins were transferred to nitrocellulose membranes, 668 
followed by blocking in TBS-T containing 10 % non-fat milk and overnight incubation 669 
with primary antibody at 4° C and light agitation (a 1:2,000 dilution was used for anti-670 
CYCLIN E antibody, and 1:1,000 for anti-p27 antibody). Immunoblots were washed 671 
three times with TBS-T, followed by incubation with the appropriate secondary 672 
antibodies (1:3,000 dilution). After 3 additional washes with TBS-T, the immunoblots 673 
were exposed to enhanced chemiluminescence reagent. Detection was performed by 674 
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exposure of the immunoblot to x-ray film. Additional cellular proteins include: anti-α-675 
TUBULIN (1:2,000) and anti-UBE2R1 (1:5,000). 676 
Comparison of UBE2R1 and UBE2R2 mRNA expression levels in WT or UBE2R1 677 
knockout 293T-FiTx cells by real-time PCR.  Cells were seeded onto 6-well tissue 678 
culture plates at 60 -80 % confluency. After 72 hours, cells were treated with trypsin 679 
solution to remove them from the tissue culture plates. Half of the cells were used for 680 
Western blotting analysis, and the other half were processed for mRNA extraction using 681 
the RNeasy mini kit (Qiagen). The mRNA levels were quantified using a nanodrop 682 
spectrophotometer, and equal amounts were used for cDNA synthesis using the 683 
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen). The cDNA 684 
samples were included in PCR reactions containing SsoAdvanced Universal SYBR 685 
Green Supermix (BioRad) and primers corresponding to amplicons for UBE2R1, 686 
UBE2R2, or GAPDH as a control (Supplementary File 1). PCR reactions were 687 
performed on a Bio-Rad CFX96 Real-Time PCR Detection System. The relative 688 
expression ratios were calculated according to the Pfaffl method.  689 
Generation of a UBE2R1/2 double knockout using CRISPR Cas9 technology. 690 
UBE2R1/2 knockout cell lines were obtained by transfecting HEK 293T cells (ATCC) 691 
with pSpCas9(BB)-2A-Puro (pX459) plasmids encoding small guide sequences 692 
targeting either UBE2R1 or UBE2R2. UBE2R1/2 double knockout clones were 693 
generated by sequential knockout of either UBE2R1 then Ube2R2 or vice versa. Two 694 
small guide sequences were synthesized targeting either locus (Supplementary File 1) 695 
and inserted into the BbsI restriction site of pX459. The transfected cell population was 696 
selected in puromycin for 2 days, and surviving cells were then cloned by serial dilution. 697 
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Cell clones were expanded and then screened at the protein level by Western blotting of 698 
total cell lysates with isoform specific antibodies (Figure 5 -figure supplement 2). Clones 699 
that showed a loss of protein expression were verified at the DNA level by sequencing. 700 
Flanking sequences of the Cas9 target site were amplified by PCR, followed by Sanger 701 
sequencing. If the resulting sequence traces showed overlapping sequences 702 
(suggestive of heterozygocity), the PCR products were cloned into TOPO TA plasmids, 703 
and DNA isolated from individual colonies were sequenced until the DNA sequences for 704 
both alleles were obtained. 705 
Knockout rate at the protein level was 7 out of 11 clones screened for UBE2R1 706 
clones, 8 out of 11 for UBE2R2 clones, 11 out of 17 for UBE2R1 knockout followed by 707 
UBE2R2 knockout, and 7 out of 7 for UBE2R2 knockout followed by UBE2R1. DNA 708 
sequencing of the Cas9 target site was carried out on 4 protein-negative clones for each 709 
category and all proved to harbor biallelic indels causing protein termination. 710 
Determination of the steady-state stabilities of β-CATENIN, CYCLIN E, and p27. 711 
Control or UBE2R1/2 double knock-out 293T cells were seeded onto 10 cm tissue 712 
culture plates at 10 % confluency and were incubated under standard tissue culture 713 
conditions for 48 hours. For the analysis of p27, CYCLIN E, and β-CATENIN proteins, 714 
cells were washed with DPBS, followed by the introduction of 1x SDS-PAGE loading 715 
buffer directly to the plate. Following brief sonication, samples were boiled for 5 minutes, 716 
and centrifuged at maximum speed using a table top microcentrifuge. Equivalent 717 
volumes of lysate were loaded onto 4-20 % Tris-Glycine SDS-PAGE gels and subjected 718 
to electrophoresis. Immunoblotting was performed as described above. A 1:2,000 719 
dilution was used for anti-β-CATENIN antibody (the same dilutions were used for p27 720 
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and CYCLIN E as described above). Additional cellular proteins include: anti-α-721 
TUBULIN (1:5,000), anti-UBE2R1 (1:5,000), anti-ARIH1 (1:500), anti-Ube2R2 (1:2000), 722 
and anti-UBE2D3 (1:5,000). 723 
 For quantitation of the steady-state protein levels, Western blots were processed 724 
as described above and incubated in primary antibody overnight. Blots were then 725 
washed three times with TBS-T and incubated with StarBright B700 (BioRad) secondary 726 
antibodies (1:3000) for approximately 1 hour. Blots were incubated at room-temperature 727 
in the dark, followed by 4 to 6 washes with TBS-T. Western blots were imaged on a 728 
BioRad ChemiDoc MP gel imaging system. Quantitation of the protein levels was 729 
accomplished in Image Lab (BioRad) by first correcting for protein loading using the α-730 
TUBULIN levels present in each lane. The corrected values for protein levels were first 731 
averaged across all of the lanes and then used to normalize the total signal for each 732 
protein in each lane.  733 
Cycloheximide chase to determine the stability of p27 in control and UBE2R1/2 734 
double knockout cells. Cells were seeded onto 6-well plates at approximately 60 % 735 
confluency late in the day and incubated overnight. Cells were then treated with 100 736 
g/mL cycloheximide and time-points were collected at 0, 1, 3 and 6 hours. Cells were 737 
washed once with DPBS, and collected as described above. Western blots with 738 
quantitation were performed identical to those described in the previous section.   739 
TNFα induced degradation of IBα protein. Control or UBE2R1/2 double knockout 740 
293T cells were seeded onto 6-well tissue culture plates with approximately 0.5 x106 741 
cells per well in starvation media (DMEM supplemented with 0.1 % fetal bovine serum, 742 
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400 g/mL Bovine Serum Albumin, 4 mM L-Glutamine, 100 units/mL Penicillin and 100 743 
g/mL Streptomycin) overnight. The next day, 100 g/mL cycloheximide was added to 744 
the media. After 5 minutes, TNFα was added to each well (50 ng/mL final). At the 745 
indicated time-points, the cells were washed once with 2 mL of DPBS, followed by the 746 
addition of 1x SDS-PAGE loading buffer directly to the plate and immediate collection of 747 
the lysate into Eppendorf tubes. Lysates were briefly sonicated, followed by boiling for 5 748 
minutes, and centrifugation in a table top microcentrifuge at the maximum setting for 2 749 
minutes. Equal amounts of sample were loaded to 4-20 % Tris-Glycine SDS-PAGE gels, 750 
followed by quantitative immunoblotting as described above (the anti-IBα antibody was 751 
diluted 1:1,000).  752 
Cell cycle analysis by flow cytometry. WT or UBE2R1/2 double knockout cells were 753 
seeded onto 6-well tissue culture plates at approximately 60% confluency and 754 
incubated for 48 hours under typical tissue culture conditions. Cells were then 755 
trypsinized and grown on a 10 cm dish for an additional day. A minimum of 300,000 756 
cells were collected by centrifugation at 1,500 x g for 5 minutes. Cell pellets were 757 
resuspended in 1 mL of cold PBS and then recollected by centrifugation as described 758 
above. Cell pellets were resuspended in 100 µL cold PBS and fixed by adding 900 µL 759 
cold ethanol dropwise while gently vortexing. Fixed cells were stored at 4° C for a 760 
minimum of 24 hours and then centrifuged as above to remove ethanol. Cells were re-761 
suspended in 300 µL of propidium iodide staining solution containing a 1:1:1 ratio by 762 
volume of propidium iodide (150 µg/mL), Triton X-100 (0.1%), and Ribonuclease A (1 763 
mg/mL), transferred to round bottom tubes (Falcon) and incubated in the dark at room 764 
temperature for 20 minutes before being placed on ice to be analyzed. Flow cytometry 765 
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was performed on a BD FACSCalibur flow cytometer with BD CellQuest Pro software 766 
for the acquisition, a 488-nm laser for the excitation, and measuring the emission in the 767 
FL2 detector with a 585/42 nm emission filter. The samples were run at a low flow rate 768 
and 20,000 events were collected. The cell cycle analysis was determined by histogram 769 
plots of the fluorescent signal in the FL2-A verses counts using FlowJo 7.6.5 software 770 
(Tree Star). 771 
Generation of UBE2R1 and UBE2R2 knockout populations and genome-wide 772 
CRISPR screens. sgRNAs for Cas9-mediated generation of UBE2R1 and UBE2R2 773 
single and double knockout populations were drawn from the previously described 774 
Extended Knockout (EKO) sgRNA library (Bertomeu et al., 2018), and are also 775 
represented in an earlier sgRNA library (T. Wang et al., 2014). Additional sgRNAs that 776 
targeted the AAVS1 locus and GFP were used as inert targeting sequences to control 777 
for the effects of multiple lentiviral infections. The sgRNA targeting sequences used are 778 
shown in Supplementary File 1. 779 
To allow iterative infections with up to three series of sgRNA lentiviral constructs 780 
selectable under different antibiotics, the previously described plasmid pLX-sgRNA 2X 781 
BfuA1 (Bertomeu et al., 2018) was modified to change the cloning cassette and the 782 
selection marker. A 1032 bp AAVS1 insert filler was amplified with oligos 783 
(Supplementary File 1) from pLX-sgRNA 2X BfuA1 and cloned into pLX-sgRNA 2X 784 
BfuA1 digested with BfuA1 by Gibson assembly to create a BsiW1-based cloning 785 
cassette (both Hygromycin and Neomycin resistance genes are cut by BfuA1). The 786 
resulting plasmid was cut with BspE1 and EcoR1 to remove the blasticidin resistance 787 
gene and re-assembled by Gibson assembly with either the Hygromycin or Neomycin 788 
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resistance genes (Supplementary File 1) to generate respectively pLX-sgRNA 2X 789 
BsiW1 AAVS1 Hygro and pLX-sgRNA 2X BsiW1 AAVS1 Neo. The sgRNA cassettes 790 
were cloned into these vectors by PCR amplification and Gibson assembly as 791 
previously described (Bertomeu et al., 2018). 792 
NALM-6 knockout populations were generated by lentiviral infection with 793 
UBE2R1#1, UBE2R1#2 and AAVS1 sgRNA constructs in pLX-sgRNA 2X BsiW1 Neo 794 
followed by selection with G418 (800µg/mL) for 7 days or until uninfected controls were 795 
inviable. Subsequently, the UBE2R1#1, UBE2R1#2 and AAVS1 infected populations 796 
were re-infected with UBE2R2#1, UBE2R2#2 or GFP sgRNA lentiviruses in pLX-sgRNA 797 
2X BsiW1 Hygro, followed by selection with Hygromycin B (200 µg/mL) for 7 days (or 798 
until uninfected controls were inviable) to generate populations for double knockout 799 
generation. Finally, each dual guide cell population was transduced with a lentiviral 800 
vector (Wong et al., 2016) that expressed Cas9 from the constitutive EF1 promoter 801 
and selected on Zeocin (200 µg/mL) for 5 days or until uninfected controls were inviable. 802 
Populations were verified for UBE2R1 and/or UBE2R2 knockout after 10 and 18 days 803 
by immunoblot with antibodies against UBE2R1 (Santa Cruz) and UBE2R2 (Santa 804 
Cruz) at recommended dilutions and detection by SuperSignal West Femto 805 
chemiluminescent substrate (Thermoscientific; Figure 6 - figure supplement 1). Aliquots 806 
of each AAVS1/GFP control, UBE2R1/GFP, AAVS1/UBE2R2 and UBE2R1/UBE2R2 807 
knockout population were frozen until the start of the genome-wide EKO screens. To 808 
initiate screens, thawed aliquots of each population genotype (UBE2R1#1 + GFP + 809 
Cas9; UBE2R2#2 + AAVS1 + Cas9; UBE2R1#2 + GFP + Cas9; UBE2R2#2 + AAVS1 + 810 
Cas9; UBE2R1#1 + UBE2R2#1 + Cas9; UBE2R1#2 + UBE2R2#2 + Cas9; AAVS1 + 811 
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GFP + CAS9 negative control) were expanded and then infected with the EKO sgRNA 812 
library at an MOI of 0.36 (Bertomeu et al., 2018) and a clonal representation of 1,700 813 
cells per sgRNA, selected for 6 days with blasticidin (10 µg/mL), and allowed to grow in 814 
the absence of antibiotic selection for an additional 14 days. Cell cultures were 815 
harvested at day 0 (immediately post-blasticidin treatment) and day 14 for each screen. 816 
Genomic DNA was extracted, sgRNAs amplified by two rounds of PCR and high-817 
throughput sequencing performed on an Illumina HiSeq 2000 or a NextSeq 500 818 
instrument in multiplexed format, as previously described (Bertomeu et al., 2018) except 819 
that an internal primer within the blasticidin resistance gene was used in the first PCR 820 
step to avoid amplification of sgRNA cassettes initially used to target UBE2R1/2. Total 821 
read counts for each screen ranged between 14.8 and 26.9 million reads. High through-822 
put sequence data can be found at the GEO repository: 823 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE136175 824 
Reviewers may use access code "cfctsyowtrobfkp". 825 
Genome-wide CRISPR screen analysis. Sequences were aligned using Bowtie 2.2.5 826 
(Langmead & Salzberg, 2012) with default parameters other than the "--norc" option. 827 
sgRNA read counts from all day 0 samples were summed together to generate 828 
consensus day 0 sgRNA levels, which were used as the control for scoring each screen. 829 
Each sample was analyzed using RANKS (Bertomeu et al., 2018) with default 830 
parameters and using the non-targeting sgRNA control set that is contained in the EKO 831 
library. To control for the effects of genotype-independent fitness defects, we averaged 832 
the RANKS scores from the two control screens and subtracted these scores from 833 
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those of each knockout screen. The resulting differential RANKS scores represent the 834 
genotype-specific fitness effects of the culminative gene indels in the pooled library. P-835 
values and FDR values were estimated using a custom-generated control distribution 836 
modeling the effects of subtracting scores. RANKS scores for different replicates of a 837 
given genetic background were then averaged together. We note that UBE2G1 scored 838 
as the 108th highest ranked synthetic lethal gene deletion (RANKS score =-1.9) in one 839 
of the two UBE2R2 single knockout backgrounds. Since UBE2R2 and UBE2R1 have a 840 
high degree of sequence similarity at the DNA level, we hypothesized that the sgRNA in 841 
question might have had an off-target effect on UBE2R1 with a lower but nevertheless 842 
detectable efficiency. We compared the UBE2R2 sgRNA sequence 843 
(CGACCTCTACAACTGGGAGG) to all potential sgRNAs with an associated PAM site 844 
that target RefSeq genes and identified one site in UBE2R1 with only two mismatched 845 
bases near the beginning of the sequence (CGATCTATACAACTGGGAGG), which is 846 
where mismatches are known to have a relatively small effect on Cas9 recognition and 847 
nuclease efficiency (T. Wang et al., 2014). It is therefore likely that UBE2R1 was fully or 848 
partially deleted in a subset of cells in the UBE2R2 population generated with this 849 
sgRNA, explaining why a weak genetic interaction with UBE2G1 was observed. The 850 
other UBE2R2-targeting sgRNA did not have any predicted off-target cleavage sites 851 
with up to two mismatches and correspondingly UBE2G1 did not score strongly in the 852 
screen with this sgRNA. 853 
Validation of UBE2R1/UBE2R2/UBE2G1 genetic interaction. The genetic interaction 854 
between UBE2R1, UBE2R2 and UBE2G1 was validated in NALM-6 cells by generation 855 
of clonal UBE2R1/2 double knockout cell lines. Populations of a clone that expressed 856 
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Cas9 under doxycycline-inducible control (NALM-6 #20; (Bertomeu et al., 2018)) were 857 
generated by lentiviral infection with sgRNA constructs for each of GFP, UBE2R2#1 and 858 
UBE2R2#2 in pLX-sgRNA 2X BsiW1 Hygro, followed by selection with 200 µg/mL 859 
Hygromycin B. Cell populations were subsequently infected with lentiviral constructs for 860 
AAVS1, UBE2R1#1 and UBE2R1#2 in pLX-sgRNA 2X BsiW1 Neo, followed by 861 
selection with 800 µg/mL G418. Control, single knockout and double knockout 862 
populations were then induced with 2 µg/mL doxycycline for 5 days, after which clonal 863 
knockout cell lines were generated by serial dilution single cell cloning. Clones were 864 
confirmed for loss of UBE2R1 and/or UBE2R2 protein expression by immunoblot 865 
(Figure 6 - figure supplement 2a,b). Each cell line was then transduced with lentiviral 866 
constructs for two different sgRNAs that target the UBE2G1 locus (Supplementary File 867 
1). 868 
 After selection with blasticidin, UBE2R1, UBE2R2 or UBER1/2 double knockout 869 
clones that expressed the UBE2G1 sgRNAs were treated with 2 µg/mL doxycycline to 870 
induce generation of indels in the UBE2G1 locus. Following 6 days of doxycycline 871 
induction, single cells were seeded in 96-well plates by serial dilution and monitored for 872 
colony growth. After 21 days, individual colonies per genotype were assessed for cell 873 
number and viability by phase contrast microscopy (Figure 6 - figure supplement 2c). 874 
UBE2G1 knockdown in the UBE2R1/2 double knockout background. Control or 875 
UBE2R1/2 double knockout cells were seeded at ~60-80% confluency. The next day, 876 
cells were transfected with 25 pMoles of siRNA (Dharmacon) for either UBE2G1 or a 877 
nontargeting control (Supplementary File 1). After a 48-hour incubation period, the cells 878 
were treated with trypsin and seeded onto 10 cm dishes. Cells were incubated for an 879 
 41 
additional 24 hours and then harvested for protein analysis 3 days post transfection. 880 
Lysates were prepared and immunoblotting was performed as above (detection by both 881 
x-ray film and fluorescent secondary antibodies). The anti-HIF1α antibody was diluted 882 
1:500, and the anti-UBE2G1 antibody was diluted 1:250.  883 
Immunofluorescence microscopy. WT 293T-FiTx or 293T-FiTx UBE2R1 were 884 
seeded onto 35 mm glass bottom plates and incubated for 24-36 hours prior to fixation 885 
in 4% paraformaldehyde for 3 minutes. Cells were then washed three times in DPBS for 886 
3 minutes, quenched in 50 mM NH4Cl for 5 minutes, washed again, and permeabilized 887 
in 0.1% Triton X-100 for 30 minutes. Primary antibody (anti-UBE2R1; Abcam) was 888 
incubated overnight at 4° C, which was then repeatedly washed off in PBS-T, first every 889 
5 minutes for an hour, and again every 10 minutes for an additional hour. Secondary 890 
antibody (Alexa Fluor 488) was incubated for 1 hour at room temperature, repeatedly 891 
washed in PBS-T first every 5 minutes for two hours, and again every 10 minutes for an 892 
additional two hours. The cells were then mounted using Permount with DAPI, and 893 
imaged using a Nikon A1D confocal microscope. The images were taken as maximum 894 
projections of z-stacks (0.5μm). 895 
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Figure Legends 1103 
Figure 1. The Km values of ARIH1, UBE2D3, or UBE2R2 for β-Catenin and Cyclin E 1104 
peptide substrates were estimated for comparison with their physiological 1105 
concentrations. Multi-turnover ubiquitylation reactions were assembled in the presence 1106 
of constant amounts of SCFFBW7 and 32P-labeled Cyclin E peptide or SCFβTRCP and 32P-1107 
labeled β-Catenin peptide and increasing amounts of (a) ARIH1 protein (along with 1108 
sufficient UBE2L3 to saturate ARIH1), (b) UBE2D3, or (c) UBE2R2. In the case of 1109 
UBE2R2, mono-ubiquitylated versions of the peptide substrates were used. The 1110 
enzyme concentrations have been provided in Supplementary File 2. Reaction 1111 
velocities were calculated (see materials and methods) and plotted as a function of the 1112 
protein concentration. The data were fit to the Michaelis-Menten equation, 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =1113 
 
𝑘𝑐𝑎𝑡[𝑆]
([𝐾𝑚 + [𝑆])
, where [S] represents the substrate concentration and Km is the Michaelis 1114 
constant, using nonlinear curve fitting (Prism 8). All reactions were performed in 1115 
duplicate technical replicates. Figure supplement 1 shows representative 1116 
autoradiograms of the ubiquitylation reactions. The R2 values for the fit of the data to the 1117 
model have been provided in Table 1.  1118 
Figure 1 - figure supplement 1. Autoradiograms of the ubiquitylation reactions to 1119 
estimate the Km values of ARIH1, UBE2D3, or UBE2R2 for β-Catenin and Cyclin E 1120 
peptide substrates. (a) multi-turnover ubiquitylation reactions were assembled in the 1121 
presence of constant amounts of SCFFBW7 and 32P-labeled Cyclin E peptide and 1122 
increasing amounts of ARIH1 protein in combination with saturating UBE2L3. Each lane 1123 
represents a single ubiquitylation reaction used to calculate the reaction velocities. (b) 1124 
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same as in (a), except with β-Catenin peptide substrate and SCFβTRCP. (c) same as in 1125 
(a), except with UBE2D3 protein. (d) same as in (b), except with UBE2D3. (e) same as 1126 
in (a), except with UBE2R2 protein and mono-ubiquitylated cyclin E peptide. (f) same as 1127 
in (b), except with UBE2R2 and mono-ubiquitylated β-Catenin peptide. S0 represents 1128 
unmodified substrate, S1 represents substrate modified with one ubiquitin, etc. The data 1129 
are representative of duplicate technical replicates used to estimate Km. The enzyme 1130 
concentrations have been provided in Supplementary File 2.  1131 
Figure 2. ARIH1 is capable of generating modest poly-ubiquitin chains onto SCF-1132 
bound substrate at either saturating or more physiological concentrations. (a) 1133 
typical conditions for the single-encounter quench flow ubiquitylation reactions used to 1134 
estimate the rates of ubiquitin transfer. (b) Autoradiogram of a Cyclin E peptide 1135 
ubiquitylation reaction with ARIH1 levels (2.5 μM) sufficient to saturate the SCF complex, 1136 
where S0 represents unmodified substrate, S1 represents substrate modified with one 1137 
ubiquitin, etc. Each time-point was performed in duplicate technical replicates. (c) Data 1138 
points and fit to the kinetic model of the reaction in (b) for substrate (S0) and two 1139 
products (S1 and S2). (d) same as (b), except more physiological ARIH1 levels (Table 1140 
2) were used in the assay. (e) same as (b), except with β-Catenin peptide substrate and 1141 
SCFβTRCP. (f) same as (e), except with more physiological ARIH1 levels. Figure 1142 
supplements 1 - 9 show the reactions and/or the fit of the data to the model for UBE2D3, 1143 
UBE2R2, and combinations with ARIH1 or UBE2D3. The enzyme concentrations have 1144 
been provided in Supplementary File 2.  1145 
 1146 
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Figure 2 - figure supplement 1. Estimation of the rates of ARIH1-catalyzed 1147 
ubiquitin transfer to SCF-bound substrate. (a) Data points and fit to the kinetic model 1148 
of a ubiquitylation reaction containing Cyclin E peptide and physiological ARIH1 levels 1149 
(Table 2) (see Fig. 2 - panel d for the autoradiogram). Duplicate data points are shown 1150 
from technical replicates. (b) same as (a), except with β-Catenin peptide substrate 1151 
levels that are saturating for SCFβTRCP (autoradiogram shown in Figure 2 - panel e). (c) 1152 
same as (b), except with more physiological ARIH1 levels (also see Figure 2 - panel f).  1153 
 1154 
Figure 2 - figure supplement 2. UBE2D3 is capable of generating modest poly-1155 
ubiquitin chains onto SCF-bound Cyclin E substrate at either saturating or more 1156 
physiological concentrations. (a) Autoradiogram of a Cyclin E ubiquitylation reaction 1157 
with UBE2D3 levels sufficient to saturate the SCF complex. (b) Data points and fit to the 1158 
kinetic model of the reaction in (a) for substrate (S0) and mono-ubiquitylated product 1159 
(S1). Duplicate data points from technical replicates are shown. (c,d) same as (a,b), 1160 
except with more physiological UBE2D3 levels. The enzyme concentrations have been 1161 
provided in Supplementary File 2. 1162 
 1163 
Figure 2 - figure supplement 3. UBE2D3 is capable of generating modest poly-1164 
ubiquitin chains onto SCF-bound β-Catenin substrate at either saturating or more 1165 
physiological concentrations. (a) Autoradiogram of a β-Catenin peptide ubiquitylation 1166 
reaction with UBE2D3 levels sufficient to saturate the SCF complex. (b) Data points and 1167 
fit to the kinetic model for the reaction in panel a. Duplicate data points from technical 1168 
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replicates are shown. (c,d) same as (a,b), except with more physiological UBE2D3 1169 
levels. The enzyme concentrations have been provided in Supplementary File 2. 1170 
Figure 2 - figure supplement 4. UBE2R2 generates robust poly-ubiquitin chains 1171 
onto SCF-bound substrates when its levels are sufficient to saturate SCF. (a) 1172 
Autoradiogram of a Cyclin E ubiquitylation reaction with saturating UBE2R2 levels. 1173 
Notice that mono-ubiquitylated substrate (S1) is barely detectible since it is very rapidly 1174 
converted to S2. (b) Data points and fit to the kinetic model for the reaction in panel a. 1175 
Estimation of the rate of ubiquitin transfer from UBE2R2~ubiquitin to S1 was done 1176 
independently, since S1 levels are only approximately 1 % of the total signal and could 1177 
not be reliably fit to the model. Duplicate data points from technical replicates are shown.  1178 
(c) Autoradiogram of a mono-ubiquitylated Cyclin E peptide (S1) ubiquitylation reaction 1179 
containing SCFFBW7 and saturating levels of UBE2R2. Reactions were also carried out 1180 
in the presence of lysine-less (K0) ubiquitin, resulting in a single product (S2). (d) Data 1181 
points and fit to the single, exponential decay of S1 and the formation of S2 from the 1182 
reaction in panel c. Duplicate data points from technical replicates are shown. (e,f) 1183 
same as in (a,b), except with β-Catenin peptide substrate and SCFβTRCP. (g,h) same as 1184 
in (c,d), except with mono-ubiquitylated β-Catenin peptide substrate and SCFβTRCP. The 1185 
enzyme concentrations have been provided in Supplementary File 2. 1186 
Figure 2 - figure supplement 5. UBE2R2 activity is negligible when assayed at 1187 
physiological conditions. (a) Autoradiogram of a Cyclin E ubiquitylation reaction with 1188 
more physiological UBE2R2 levels. (b) same as in (a), except with β-Catenin peptide 1189 
substrate and SCFβTRCP. The data are representative of duplicate technical replicates. 1190 
The enzyme concentrations have been provided in Supplementary File 2. 1191 
 56 
Figure 2 - figure supplement 6. The combination of ARIH1 with UBE2R2 protein 1192 
results in Cyclin E substrates modified with longer poly-ubiquitin chains than 1193 
with ARIH1 alone. (a) Autoradiogram of a Cyclin E ubiquitylation reaction with ARIH1 1194 
and UBE2R2 levels sufficient to saturate the SCF complex. (b) Data points and fit to the 1195 
kinetic model for the reaction shown in panel a. Duplicate data points from technical 1196 
replicates are shown. (c,d) same as (a,b), except with more physiological ARIH1 and 1197 
UBE2R2 levels. The enzyme concentrations have been provided in Supplementary File 1198 
2. 1199 
Figure 2 - figure supplement 7.  The combination of ARIH1 with UBE2R2 protein 1200 
results in β-Catenin substrates modified with longer poly-ubiquitin chains than 1201 
with ARIH1 alone. (a) Autoradiogram of a β-Catenin peptide ubiquitylation reaction with 1202 
ARIH1 and UBE2R2 levels sufficient to saturate the SCF complex. (b) Data points and 1203 
fit to the kinetic model for the reaction in panel a. Duplicate data points from technical 1204 
replicates are shown. (c,d) same as (a,b), except with more physiological ARIH1 and 1205 
UBE2R2 levels. The enzyme concentrations have been provided in Supplementary File 1206 
2. 1207 
Figure 2 - figure supplement 8. The combination of UBE2D3 with UBE2R2 protein 1208 
results in substrates modified with longer poly-ubiquitin chains than with 1209 
UBE2D3 alone. (a) Autoradiogram of a Cyclin E ubiquitylation reaction with UBE2D3 1210 
and UBE2R2 levels sufficient to saturate the SCF complex. (b) Data points and fit to the 1211 
kinetic model for the reaction in panel a. Duplicate data points from technical replicates 1212 
are shown. (c,d) same as (a,b), except with more physiological UBE2D3 and UBE2R2 1213 
levels. The enzyme concentrations have been provided in Supplementary File 2. 1214 
 57 
Figure 2 - figure supplement 9. The combination of UBE2D3 with UBE2R2 protein 1215 
results in substrates modified with longer poly-ubiquitin chains than with 1216 
UBE2D3 alone, especially in the presence of β-Catenin peptide substrate. (a) 1217 
Autoradiogram of a β-Catenin peptide ubiquitylation reaction with UBE2D3 and UBE2R2 1218 
levels sufficient to saturate the SCF complex. (b) Data points and fit to the kinetic model 1219 
for the reaction in panel a. Duplicate data points from technical replicates are shown. 1220 
(c,d) same as (a,b), except with more physiological UBE2D3 and UBE2R2 levels. The 1221 
enzyme concentrations have been provided in Supplementary File 2. 1222 
Figure 3. Multiple routes to ubiquitylation: at saturating conditions, all enzymes 1223 
can prime SCF-bound substrates, but only UBE2D3 and ARIH1 can prime at 1224 
physiological concentrations. (a) quantitation of the fractions of Cyclin E substrate 1225 
(S0) and all products taken from the 10 second time-points from the quench flow 1226 
reactions in Fig. 2. Solid bars represent levels for reactions where ARIH1, UBE2D3, 1227 
and/or UBE2R2 were saturating for SCF; empty bars represent reactions containing the 1228 
same enzymes at more physiological levels (Table 2). Notice that UBE2R2 is capable of 1229 
generating substantial products with long poly-ubiquitin chains when saturating for 1230 
SCFFBW7, but produces almost no product when UBE2R2 levels are more physiological. 1231 
(b) same as in (a), except with β-Catenin peptide substrate and SCFβTRCP.  1232 
Figure 4. Altered ARIH1, UBE2D3, and/or UBE2R2 levels result in substantial 1233 
differences in both the fraction of substrate converted to product as well as the 1234 
average number of ubiquitins in poly-ubiquitin chains. Single-encounter 1235 
ubiquitylation reactions were initiated with either ARIH1, UBE2D3, or UBE2R2 alone or 1236 
relevant combinations at near cellular levels (middle panel). The same reactions were 1237 
 58 
also performed with either a 2- or 4-fold reduction in the enzyme levels (left panel), or 2- 1238 
or 4-fold greater levels (right panel). All reactions were performed in duplicate technical 1239 
replicates. Figure supplement 1 provides graphs of the relative frequencies for the 1240 
distribution of unmodified substrate and products. The enzyme concentrations have 1241 
been provided in Supplementary File 2. 1242 
Figure 4 - figure supplement 1. Modest changes to ARIH1, UBE2D3, and/or 1243 
UBE2R2 levels result in substantial differences in both the fraction of substrate 1244 
converted to products as well as the average number of ubiquitins in poly-1245 
ubiquitin chains. (a) quantitation of the fractions of substrate (S0) and all products 1246 
from the single-encounter reactions in Fig. 4 containing varying amounts of ARIH1 1247 
protein. The mid-range level was near physiological (Table 2). (b) same as in (a), except 1248 
with UBE2D3. (c) same as in (a), except with UBE2R2. (d) same as in (a), except with 1249 
both ARIH1 and UBE2R2. (e) same as in (a), except with both UBE2D3 and UBE2R2. 1250 
Data points are shown from duplicate technical replicates. 1251 
Figure 5. The ablation of both UBE2R1 and UBE2R2 proteins has no effect on the 1252 
stabilities of four SCF substrates as well as cell cycle progression. (a) Comparison 1253 
of the steady state stabilities of β-CATENIN, CYCLIN E, and p27 proteins in either 1254 
control cell lines (clones 1, G3, and D5) or UBE2R1/2 double knockout cell lines (clones 1255 
B3, E4 and A10). Demonstrations of the anti-UBE2R1 and anti-UBE2R2 antibody 1256 
specificities are provided in figure supplements 2 and 5b. (b) β-CATENIN (black circles), 1257 
CYCLIN E (gray squares), and p27 (orange diamonds) protein levels from control or 1258 
UBE2R1/2 double knockout cell lines. The median levels for each group are shown as 1259 
dashed horizonal lines. While two of the double knockout cell lines showed evident 1260 
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enrichment of p27 in comparison with control cells, this result did not meet a minimal 1261 
standard for statistical significance (p-value of 0.13 using an unpaired t-test; Prism 8). 1262 
(c) Cycloheximide chase time courses measuring p27 protein stability from either 1263 
control or UBE2R1/2 double knockout cells. Protein levels were normalized to the 1264 
untreated samples and fit to a one phase decay model (The R2 values for control and 1265 
knockout cells are 0.85 and 0.77, respectively; Prism 8). Representative Western blots 1266 
are shown in figure supplement 3a. (d) TNFα-induced degradation of IBα is 1267 
comparable in either control or UBE2R1/2 double knockout cells. Protein levels were 1268 
normalized to the untreated samples and fit to a one phase decay model (The R2 values 1269 
for control and double knockout cells are 0.77 and 0.80, respectively; Prism 8). 1270 
Representative Western blots are shown in figure supplement 3b.  (e) Cell cycle 1271 
analysis was performed on actively dividing populations of control or UBE2R1/2 double 1272 
knockout cells. Representative spectra are shown in figure supplement 4. Three 1273 
biological replicates each for control and UBE2R1/2 double knockout cell lines with 1274 
duplicate technical replicates were used to generate the data for all panels.  1275 
Figure 5 - figure supplement 1. The ablation of UBE2R1 protein has no effect on 1276 
the stabilities of CYCLIN E and p27 proteins as well as UBE2R2 expression levels. 1277 
(a) Representative data showing the stabilities of CYCLIN E and p27 proteins from a 1278 
cycloheximide (CHX) chase experiment comparing wild-type and UBE2R1 knockout 1279 
293T-FiTx cells. (b) relative expression ratios for either UBE2R1 or UBE2R2 mRNA 1280 
comparing wild-type or UBE2R1 knockout 293T-FiTx cells. Data points are shown from 1281 
duplicate technical replicates. 1282 
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Figure 5 - figure supplement 2. Antibody specificities for UBE2R1 and UBE2R2. 1283 
(a) Western blot of cellular lysates from the parental and various UBE2R1, UBE2R2 and 1284 
UBE2R1/2 knockout cell lines demonstrating the specificities of the antibodies used to 1285 
detect UBE2R1 and the closely related UBE2R2 protein (greater than 85 % amino acid 1286 
sequence identity). Notice that colony E11 shows ablation of both UBE2R1 and 1287 
UBE2R2, likely due to the high similarity of UBE2R2 guide #2 with the UBE2R1 DNA 1288 
sequence. The anti-UBE2R2 antibody was used for all Western blots throughout the 1289 
manuscript, whereas the anti-UBE2R1 antibody was used for Westerns shown in Figure 1290 
6 - figure supplements 1 and 2.   1291 
Figure 5 - figure supplement 3. The rates of degradation of p27 and IBα proteins 1292 
are highly similar in control and UBE2R1/2 knockout 293T cells. (a) Representative 1293 
Western blots for the cycloheximide chase experiment shown in Fig. 5c. (b) 1294 
Representative Western blots for the TNF-induced degradation of IBα protein (Fig. 1295 
5d). Three independent cell lines for control (clones 1, G3 and D5) and UBE2R1/2 1296 
double knockout (clones B3, E4, and A10) cells were used to generate the data for both 1297 
panels with duplicate technical replicates.  1298 
Figure 5 - figure supplement 4. The ablation of UBE2R1 and UBE2R2 proteins has 1299 
no effect on 293T cell cycle progression. Representative flow cytometry profiles for 1300 
three control (clones 1, G3 and D5) and three UBE2R1/2 double knockout (clones B3, 1301 
E4, and A10) cell lines. Duplicate technical replicates were used to generate the graph 1302 
shown in Fig. 5e.  1303 
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Figure 5 - figure supplement 5. UBE2R1 protein is localized throughout 293T-FiTx 1304 
cells. (a) Immunofluorescence staining of UBE2R1 protein (green; middle panel). 1305 
UBE2R1 protein is visible with modest evident nuclear enrichment, to a lesser extent in 1306 
the cytoplasm, and in adjacent pairs of foci. Scale bar, 5 μM. (b) Immunofluorescence 1307 
staining for UBE2R1 protein (green; middle panel) performed on HEK 293T-FiTx 1308 
UBE2R1 knockout cells. Notice that no UBE2R1 staining is observed. Scale bar, 20 μM. 1309 
Representative data are shown from duplicate biological replicates.  1310 
Figure 5 - figure supplement 6. Generation of a UBE2R1 knockout cell line. (a) 1311 
Products from PCR reactions spanning the UBE2R1 exon 2 guide RNA site were 1312 
resolved by agarose gel electrophoresis. Incorporation of the oligo DNA (see 1313 
Supplementary File 1 - Key Resources Table) into the genome should increase the 1314 
PCR product by 50 base pairs. Notice that upward shifts were observed for multiple 1315 
clones, such as 9 and 32. The results are representative of duplicate technical 1316 
replicates. (b) Demonstration of the specificity of an anti-UBE2R1 antibody with 1317 
recombinant UBE2R1 and UBE2R2 proteins. This antibody was used to generate 1318 
Western blots shown in Fig. 5a, Fig. 5 - figure supplement 1, and Fig. 7a.  1319 
Figure 6. A genome-wide CRISPR fitness screen identifies UBE2G1 as the primary 1320 
genetic vulnerability of a UBE2R1/2 double knockout cell line. (a) Schematic of 1321 
CRISPR screen workflow to identify genes that cause synthetic lethality in a UBE2R1/2 1322 
double mutant background. (b) Scatter plot of differential RANKS scores of all genes in 1323 
replicate UBE2R1/2 double knockout screens. Negative values indicate sgRNA 1324 
depletion relative to the control population background and positive values indicate 1325 
sgRNA enrichment. (c,d). Scatter plot comparisons of differential RANKS scores for 1326 
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UBE2R1/2 double knockout compared to UBE2R2 and UBE2R1 screens. For both plots, 1327 
UBE2R1/2 scores are the average of the two screens in panel b. (e) Scatter plot 1328 
comparison of UBE2R1 versus UBE2R2 screens. Scores for UBE2R2 screens are the 1329 
average of two independent replicates, whereas scores for UBE2R1 are from a single 1330 
screen. 1331 
Figure 6 - figure supplement 1. Knockout populations for control, UBE2R1 and 1332 
UBE2R2 loci used in genome-wide CRISPR screens. NALM-6 populations treated 1333 
with sgRNAs that target AAVS1, GFP, UBE2R1 and/or UBE2R2 as indicated. UBE2R1 1334 
and UBE2R2 protein were detected by immunoblot with anti-UBE2R1 or anti-UBE2R2 1335 
antibody at 1:1000 dilution. Note that since CRISPR-mediated knockout populations 1336 
were not clonal, residual protein was detected in some instances. 1337 
Figure 6 - figure supplement 2. Proliferation defect of UBE2R1/UBE2R2/UBE2G1 1338 
triple knockout NALM-6 cells.  (a) Loss of UBE2R1 and UBE2R2 protein in clonal 1339 
knockout NALM-6 cell lines for the UBE2R1 locus (top) or UBE2R2 locus (middle) or 1340 
both loci (bottom). Clones used for analysis in panel b and c are indicated by red boxes. 1341 
(b) Loss of UBE2G1 protein in AAVS1/GFP control and UBE2R1/UBE2R2 double 1342 
knockout NALM-6 cell lines populations treated with indicated lentiviral constructs that 1343 
target either control AZ-Green or UBE2G1. (c) Viability of colonies for the indicated 1344 
combinations of UBE2R1, UBE2R2 and UBE2G1 knockouts. All cell lines and 1345 
populations for validation experiments were generated in the NALM-6 doxycycline-1346 
inducible Cas9 clone #20 background. 1347 
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Figure 7. UBE2G1 functions redundantly with UBE2R1/2 and SCF in cells. (a) 1348 
Comparison of the steady state stabilities of HIF1, CYCLIN E, and p27 proteins in HEK 1349 
293T control or UBE2R1/2 double knockout cells treated with siRNA targeting UBE2G1 1350 
expression. (b) Quantitative comparison of the steady state levels for HIF1 (open or 1351 
closed black circles), CYCLIN E (open or closed gray squares), and p27 protein (open 1352 
or closed orange diamonds). P-values were calculated using an unpaired t-test (* and ** 1353 
denote values of less than 0.05 or 0.01, respectively; Prism 8). P-values for all relevant 1354 
combinations are provided in Figure 7 - source data 1. Three biological replicates each 1355 
for control and UBE2R1/2 double knockout cells were used to generate the figure with 1356 
duplicate technical replicates.  (c) Representative autoradiogram of a Cyclin E peptide 1357 
ubiquitylation reaction with either ARIH1, UBE2D3, or UBE2G1 alone or in combination. 1358 
(d) graphical representation of the levels of unmodified substrate and ubiquitylated 1359 
products from the reactions shown in panel c. Duplicate technical replicates were 1360 
performed to generate the figure. Source data have been provided in Figure 7 - source 1361 
data 2 for panel d. (e) Representative autoradiogram of a Cyclin E ubiquitylation 1362 
reaction with UBE2G1 levels (12.5 μM) sufficient to saturate the SCF complex. Figure 1363 
supplement 7 - 1d shows the fit of the data to the kinetic model. The enzyme 1364 
concentrations have been provided in Supplementary File 2. 1365 
Figure 7 - figure supplement 1. UBE2G1 displays robust activity in the presence 1366 
of mono-ubiquitylated peptide substrates. (a) Single encounter ubiquitylation 1367 
reactions containing either saturating UBE2R2 or UBE2G1 and mono-ubiquitylated β-1368 
Catenin peptide substrate and SCFβTRCP or mono-ubiquitylated Cyclin E peptide 1369 
substrate and SCFFBW7. Reactions were quenched at 10 seconds (see materials and 1370 
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methods). (b) multi-turnover ubiquitylation reactions were assembled in the presence of 1371 
constant amounts of SCFFBW7 and 32P-labeled Ub-Cyclin E peptide and increasing 1372 
amounts of UBE2G1 protein. Each lane represents a single ubiquitylation reaction used 1373 
to calculate the reaction velocity (see materials and methods). Representative data from 1374 
two technical replicates are shown for panels (a) and (b). (c) The velocities from the 1375 
reactions in (b) were plotted as a function of the UBE2G1 protein concentration and the 1376 
data were fit to the Michaelis-Menten equation, 𝑣𝑒𝑙𝑜𝑐𝑖𝑡𝑦 =  
𝑘𝑐𝑎𝑡[𝑆]
([𝐾𝑚 + [𝑆])
, using nonlinear 1377 
curve fitting (Prism 8). Data points are shown from duplicate technical replicates. (d) 1378 
Data points and fit to the kinetic model of the reaction in Fig. 7d for mono-ubiquitylated 1379 
substrate. Data points are shown from duplicate technical replicates. All relevant 1380 
enzyme concentrations have been provided in Supplementary File 2. 1381 
Figure 8. SCF-catalyzed substrate ubiquitylation is extensively buffered at the 1382 
initiation and elongation steps in human cells compared to the simper yeast SCF 1383 
system. UB, ubiquitin.  1384 
  1385 
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Table 1. Estimates of Km and kcat for Substrate Ubiquitylation 1386 
Substrate Chain 
modifying E2 
or E3 
E3 Km (10
-9 M) kcat (min
-1) R2 
Cyclin E ARIH1 SCFFBW7 149 ± 36 0.29 ± 0.02 0.90 
β-Catenin ARIH1 SCFβTRCP 486 ± 138 0.32 ± 0.03 0.87 
Cyclin E UBE2D3 SCFFBW7 1673 ± 460 0.77 ± 0.06 0.89 
β-Catenin UBE2D3 SCFβTRCP 488 ± 53 1.9 ± 0.04 0.97 
Cyclin E UBE2R2 SCFFBW7 ND ND  
β-Catenin UBE2R2 SCFβTRCP *1900 ± 100   
Ub-Cyclin E UBE2R2 SCFFBW7 317 ± 44 3.7 ± 0.1 0.96 
Ub-β-Catenin UBE2R2 SCFβTRCP 292 ± 35 3.2 ± 0.1 0.97 
Ub-Cyclin E UBE2G1 SCFFBW7 1300 ± 20 2.3 ± 0.1 0.96 
              *(Hill, Hill, & Kleiger, 2018); ND, not determined. 1387 
*(Hi 1388 
                      1389 
  1390 
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 1391 
Table 2. Estimates of the cellular concentrations of SCF-related E2s and E3s in four 1392 
common cell lines (10-9 M ± SEM) 1393 
 293T-FiTx 293T/17 HeLa MRC5 
ARIH1 200 ± 10 148 ± 7 200 ± 10 160 ± 10 
UBE2D1/2/3/4 2100 ± 100 1700 ± 100 1875 ± 7 1770 ± 40 
UBE2R1 70 ± 3 134 ± 3 83 ± 2 82 ± 2 
UBE2R2 132 ± 7 99 ± 6 280 ± 30 117 ± 1 
CUL1 300 ± 20 340 ± 10 134 ± 5 176 ± 1 
SKP1 2300 ± 100 1173 ± 9 1860 ± 20 1440 ± 40 
details on the calculations are provided in Table 2 - source data 1 1394 
 1395 
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Table 3. Estimates of the rates of ubiquitin transfer to substrate kobs (sec
-1) 1396 
 Substrate prior to ubiquitin transfer* 
Substrate 
Chain modifying 
E2 or E3 
E3 S0 S1 S2 
Cyclin E ARIH1 SCFFBW7 0.5 ± 0.04 (0.2 ± 0.005) 0.2 ± 0.03 (0.1 ± 0.01) 0.08 ± 0.01 (0.1 ± 0.02) 
β-Catenin ARIH1 SCFβTRCP 0.2 ± 0.01 (0.1 ± 0.005) 0.3 ± 0.07 (0.2 ± 0.02) ND (0.1 ± 0.02) 
Cyclin E UBE2D3 SCFFBW7 0.1 ± 0.01 (0.06 ± 0.003) 0.2 ± 0.08 (0.2 ± 0.03) ND (ND) 
β-Catenin UBE2D3 SCFβTrCP 5 ± 0.6 (3 ± 0.2) 0.2 ± 0.04 (0.2 ± 0.03) ND (0.5 ± 0.1) 
Cyclin E UBE2R2 SCFFBW7 0.2 ± 0.02 (ND) 40 ± 4 (ND) 4 ± 0.5 (ND) 
β-Catenin UBE2R2 SCFβTrCP 0.1 ± 0.01 (ND) 30 ± 3 (ND) 7 ± 0.5 (ND) 
Cyclin E ARIH1/UBE2R2 SCFFBW7 0.2 ± 0.06 (0.2 ± 0.006) ND (0.4 ± 0.03) ND (1 ± 0.1) 
β-Catenin ARIH1/UBE2R2 SCFβTrCP 0.3 ± 0.05 (0.07 ± 0.006) 2 ± 0.6 (0.6 ± 0.08) 5 ± 0.8 (1 ± 0.1) 
Cyclin E UBE2D3/UBE2R2 SCFFBW7 0.2 ± 0.01 (0.1 ± 0.006) 7 ± 1 (3 ± 0.4) 4 ± 0.3 (2 ± 0.1) 
β-Catenin UBE2D3/UBE2R2 SCFβTrCP 4 ± 0.5 (3 ± 0.3) 0.9 ± 0.1 (0.4 ± 0.04) 4 ± 0.4 (1 ± 0.1) 
Ub-Cyclin E UBE2G1 SCFFBW7 ND (ND) 1.0 ± 0.1 (ND) 1.0 ± 0.1 (ND) 
*Rates are given for both saturating E2/E3 for SCF or for estimated cellular E2/E3 for SCF (in parenthesis and italics). P-1397 
values for the goodness of fit to the model are provided in Table 3 - Source Data 1.  1398 
ND; not determined or not statistically significant. 1399 
 1400 
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Appendix 1. SCFβTRCP and SCFFBW7 are ideal choices for comparing the priming 1 
and ubiquitin-chain extending activities of ARIH1, UBE2D3, UBE2R2 and 2 
UBE2G1.  3 
 4 
 For comparing the ubiquitin-conjugating activities of ARIH1, UBE2D3, 5 
UBE2R2 and UBE2G1, human SCF ligases based on the βTRCP substrate receptor 6 
(SCFβTRCP) and the FBW7 substrate receptor (SCFFBW7) were chosen for two major 7 
reasons. First, both the substrate and substrate receptors of these enzymes are of 8 
critical biological importance. For instance, the βTRCP substrate β-CATENIN 9 
functions in WNT signaling, and the impairment of this pathway has been linked to 10 
various forms of cancer as well as diabetes. Another βTRCP substrate, IKB, is a 11 
master regulator of inflammation signaling in humans. Furthermore, βTRCP is an 12 
oncogene whose over-expression has been observed in multiple cancers. While 13 
FBW7 is itself a tumor suppressor, its substrate CYCLIN E is an oncogene, with 14 
multiple cancers displaying CYCLIN E gene amplification. Thus, a detailed 15 
mechanistic understanding for how these SCF complexes function is of clear 16 
biological and medical relevance.  17 
 Second, when performing kinetics by quench flow, one must consider the 18 
ability to mass produce recombinant proteins. For instance, consider that a single 19 
shot in the Kintek RQF-3, the instrument used for this study, consumes 20 
approximately 50 L of liquid volume. Since the final SCF concentration is 0.5 M in 21 
the pre-steady state reactions, it is apparent that crystallographic quantities of 22 
proteins are required for the multiple time-points and multiple comparisons that were 23 
made between the enzymes, as well as the duplicate technical replicates. Full-length 24 
βTRCP protein can be expressed and purified from insect cells in reasonable 25 
quantities, and also has the advantage that it contains a dimerization domain, which 26 
often is important for optimal SCF activity (Tang et al., 2007).  27 
 28 
Appendix 1 Figure 1. Reactions were assembled in two separate mixtures: an 29 
E1/E2 mix that contained excess unlabeled Cyclin E peptide (tube 1) and an SCF-30 
32P-labeled substrate mix (1 μM SCF, 0.2 μM substrate; tube 2). Following addition of 31 
10 μM E2 and/or 2.5 μM ARIH1 to tube 1 already containing reaction buffer (30 mM 32 
Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM MgCl2, 2 mM DTT and 2 mM ATP), E1 (0.5 33 
μM) and ubiquitin (80 μM), each mix was incubated at room temperature for at least 8 34 
minutes. The E1/E2 mix was then pipetted into the SCF/substrate mix initiating the 35 
reaction, which was then briefly vortexed and quenched in reducing 2x loading SDS-36 
PAGE buffer after 10 seconds. The reactions were resolved by SDS-PAGE and 37 
visualized by autoradiography. All reactions were performed in duplicate. 38 
 39 
 Producing full-length FBW7 protein at the quantities that are required for 40 
quench flow was impractical. However, a unique exception to the importance of 41 
substrate receptor dimerization and SCF activity is that high affinity substrates, such 42 
as the Cyclin E peptide employed here, are ubiquitylated with similar efficiencies by 43 
dimeric or monomeric SCF complexes (Tang et al., 2007; Welcker et al., 2013). We 44 
demonstrated in the above figure that this is indeed the case for ARIH1, UBE2D3, 45 
and UBE2R2.  46 
 In summary, SCFβTRCP and SCFFBW7 are logical choices for E3 enzyme and 47 
quantitative kinetics given their tremendous biological importance and amenability to 48 
the assay.  49 
Appendix 2. Demonstrating the structural integrities and fractional activities of 1 
the E2 enzymes employed in this study.  2 
 3 
 E2 loading experiments (mass spectra shown below) indicate that both 4 
UBE2R2 and UBE2G1 were fully loaded with ubiquitin, indicating that 100 % of the 5 
protein in those preparations are active. UBE2L3 was charged at 65 % efficiency, 6 
and 52 % of UBE2D3 was charged (please see Appendix 2 - source data 1). The 7 
following summarizes the main conclusions of the manuscript and how the above 8 
enzyme activities pertain to them: (1) The rates of poly-ubiquitin chain extension are 9 
faster for UBE2R2 in comparison with UBE2G1, in particular for ubiquitin transfer to 10 
a mono-ubiquitylated substrate. The conclusion is valid since each enzyme is 100 % 11 
active. (2) UBE2D3 displays specificity for the substrate and/or the substrate 12 
receptor protein. The conclusion is valid since the same fraction of active enzyme 13 
are being compared in both cases (e.g. the substrate receptor and peptide differ). (3) 14 
The rates of ubiquitin chain initiation in ARIH1- or UBE2D3-catalyzed reactions are 15 
not substantially affected by enzyme concentrations that range from physiological to 16 
saturating levels. The conclusion is valid because the same fraction of active E2 or 17 
E3 enzymes are compared in both cases. (4) While the rates of ubiquitin chain 18 
initiation by UBE2R2 when saturating for SCF are comparable to those of ARIH1 and 19 
UBE2D3, UBE2R2 clearly cannot support ubiquitin chain initiation or ubiquitylated 20 
product formation when present at physiological levels. The comparison of the 21 
activities of UBE2R2, UBE2D3 and ARIH1 does require further clarification based on 22 
the activity of each recombinant enzyme.  23 
 With regard to ARIH1 activity, even though 65 % of the UBE2L3 enzyme is 24 
charged, the kinetics are performed with a 4-fold excess of UBE2L3 compared with 25 
ARIH1 (please see Supplementary File 2), and the Km measurements are also done 26 
with at least a 4-fold excess as well. Thus, the amount of charged UBE2L3 in the 27 
reaction likely exceeds the amount of ARIH1.  28 
 Finally, some 52 % of UBE2D3 was charged with ubiquitin upon quenching. 29 
However, this does not necessarily mean that only 52 % of the UBE2D3 was active 30 
in the preparation. For instance, the UBE2L3~ubiquitin and UBE2D3~ubiquitin 31 
thioester bonds may be susceptible to hydrolysis. Furthermore, the mass-spec 32 
results show that UBE2D3~ubiquitin and UBE2L3~ubiquitin react with DTT (please 33 
see Appendix 2 - source data 1 for a detailed account of the species present in the 34 
E2 loading reactions and their abundances). This is clearly specific for UBE2D3 and 35 
UBE2L3, since ubiquitin~DTT is not observed in loading reactions with UBE2G1 or 36 
UBE2R2. Thus, it is highly likely that these factors lead to partial disruption of 37 
UBE2L3~ubiquitin and UBE2D3~ubiquitin bonds and cause underestimation of the 38 
active E2 fraction in these reactions. Nevertheless, it remains possible that UBE2D3 39 
activity may not be 100 %, and the Km measurements and ubiquitin transfer rates for 40 
those reactions may be underestimated to some extent.  41 
 42 
 43 
Appendix Figure 1. ARIH1, UBE2D3, UBE2R2, UBE2L3 and UBE2G1 all show 44 
single, monodisperse peaks by gel filtration chromatography. To demonstrate 45 
the overall structural integrities of the E2s and ARIH1 that were characterized in this 46 
study, proteins that had previously been purified and flash frozen in liquid nitrogen 47 
for long-term storage were injected onto a Superdex 75 increase 10/300 gl column 48 
that had been equilibrated in a buffer containing 30 mM Tris, pH 7.5, 100 mM NaCl, 49 
1 mM DTT, and 10 % glycerol. The absorbance at 280 nM (A280) was normalized for 50 
all chromatograms.  51 
 52 
 53 
 54 
Appendix Figure 2. Mass spectra for control ubiquitin loading reaction 55 
containing UBE2D3. Mass spectrum for a negative control ubiquitin charging 56 
reaction containing UBE2D3 (10 µM), E1 (1 µM) and wild-type human ubiquitin (15 57 
µm) in reaction buffer without ATP (30 mM Tris, pH 7.5, 100 mM NaCl, 5 mM MgCl2, 58 
and 1 mM DTT). The reaction components were incubated at room temperature for 5 59 
minutes, then quenched by adding 90 L of 5% acetic acid. The detection of proteins 60 
was performed on an Agilent LC-MSD. Mass spectra were acquired in positive-ion 61 
mode, scanning from 500 to 1700 m/z. The electrospray voltage was set to 4 kV and 62 
the gas temperature in the spray chamber was maintained at 350 °C. A stationary 63 
phase, Zorbax 300SB C3 150 mm × 2.1 mm column was used for separation 64 
(Agilent). The mobile phase A buffer was 0.2% formic acid, and the mobile phase B 65 
was 0.2% formic acid with 10% methanol and 90% acetonitrile. The flow rate was 66 
0.2 ml min-1. After a 25-minute delay, the effluent was directed into the mass 67 
spectrometer. Linear gradients started with 5% mobile phase B and finished at 95% 68 
from 25–50 min. Data were processed using the ChemStation software package. 69 
Deconvolution of the spectra into the observed species and their abundances is 70 
shown in Appendix 2 - source data 1. Dotted blue lines are shown where peaks 71 
would be expected for UBE2D3~ubiquitin. Notice that none were found in the 72 
absence of ATP.  73 
 74 
Appendix Figure 3. Mass spectra for ubiquitin loading reactions containing the 75 
E2s that were characterized in this study. (a) Same as in Appendix Figure 2, 76 
except with ATP present in the reaction buffer. (b) same as (a), except with 77 
UBE2G1. (c) same as (a), except with UBE2R2. (d) same as (a), except with 78 
UBE2L3.  79 
 80 
   81 
 82 
 83 
 84 
 85 
 86 
  87 
Appendix Figure 4. UBE2D2 and UBE2D3 show identical activities in a SCF-88 
dependent substrate ubiquitylation assay. (a) Ubiquitylation reactions were 89 
performed under single-encounter conditions (see materials and methods) with 90 
SCFβTRCP and β-Catenin peptide substrate. The E2 concentrations were 490 nM or 91 
100 nM, which are equal to or one-fifth of the Km of UBE2D3 for SCF
βTRCP, 92 
respectively. These concentrations were chosen to probe for potential defects in both 93 
E2 binding to E3 (differential effects on substrate consumption when comparing the 94 
reactions at these E2 concentrations) or the rate of ubiquitin transfer (differential 95 
effects on the degree of poly-ubiquitin chain elongation). 96 
76nM H5b/H5c or 195nM H5b/H5 97 
 98 




























